WO1998052632A1 - Injection apparatus - Google Patents
Injection apparatus Download PDFInfo
- Publication number
- WO1998052632A1 WO1998052632A1 PCT/US1998/008161 US9808161W WO9852632A1 WO 1998052632 A1 WO1998052632 A1 WO 1998052632A1 US 9808161 W US9808161 W US 9808161W WO 9852632 A1 WO9852632 A1 WO 9852632A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- syringe
- injector
- cartridge
- compressed gas
- pressure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock
- A61M2005/208—Release is possible only when device is pushed against the skin, e.g. using a trigger which is blocked or inactive when the device is not pushed against the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2053—Media being expelled from injector by pressurised fluid or vacuum
Definitions
- This invention relates to a needle-free or needleless hypodermic injection device used to subcutaneously inject medication into the skin of a patient.
- an injection system there are many attributes which are highly desirable in an injection system, whether it is of the type that uses a needle and syringe, or is of needleless configuration. It is necessary to accurately meter a dose, and to permit the dose to be varied from injection to injection. It is also highly desirable that the injection system be capable of use by the patients themselves, and be usable by someone with limited physical capabilities. For example, physically disabled patients are often in need of regular medication. Some patients have particular difficulty with motor control, and yet to live an independent life, they need to be able to self-administer injections. Needleless injection systems are suitable for these types of patients because one of the common problems is that it is difficult for them to grasp and manipulate a smaller object such as a syringe. It is also desirable that the system can be used, that is, loaded, manipulated, and administered, by one who has had no medical training and who has had little training or experience in the use of the injection system.
- a needleless injection system there are a number of attributes which need to be considered which are not necessarily present when a conventional syringe and needle-type system is used.
- the needleless injection system needs to be positioned directly against and roughly perpendicular to the skin of the patient. This is not a factor when the skin is being pierced with a needle.
- any needleless injection system using compressed gas needs to have adequate compressed gas loading pressure in order to prevent misfiring or improper application of medication.
- the needleless injection system using compressed gas needs to have adequate compressed gas loading pressure in order to prevent misfiring or improper application of medication.
- SUBSTITUTE SHEET ( ruie 26 ) loading of pressure within the injection system needs to be performed in a predictable, repeatable fashion so that the pressure is precisely loaded.
- Some existing equipment includes a turn down screw which pierces a compressed gas vessel. But during the turning down operation, gas pressure is lost, and the amount of lost pressure varies directly with the rate at which the screw is turned. This will normally not affect the proper operation of the injector, but it may well reduce the number of injections possible with a single cartridge.
- Another desirable feature in needleless injection systems is that the units be relatively inexpensive, be virtually maintenance free, and be able to last for an appropriate period of time. Not only are patients who utilize these products often supported by fixed incomes, but because they are often disabled, they may not recognize that there is a problem with a unit which is prone to breakdown or which needs regular maintenance. Therefore, reliability is an important advantage, as well as the ease of use previously discussed.
- One problem which exists with some of the prior injection systems is that it is difficult to fill the ampule with a precise measurement of medication in a process which is simple and which, again, may be performed by someone who has difficulty handling small objects or who is otherwise disabled.
- the present invention typically is in the form of a needleless injector which includes the following components: (1) a needleless syringe installed in the injector for holding medication prior to injection, the syringe including an injection aperture at the forward end thereof; (2) a syringe plunger slidably mounted to the rear end of the syringe for forcing medication out the syringe aperture; (3) a syringe plunger drive mechanism providing power to drive the syringe plunger and thereby force medication out of the syringe; and (4) a syringe drive control mechanism for controlling the operation of the drive mechanism, the drive control mechanism including a warning system which warns the user if a pre-injection condition is not met, an interlock system which prevents injection from taking place if the pre-injection condition is not met, and a sensing system which senses whether the pre-injection condition is not met and conveys a signal to the warning and interlock systems informing as to whether the pre-injection condition
- a needleless injection system which includes a needleless syringe including an ampule for holding medication to be injected, and a plunger reciprocable with respect to the ampule for drawing medication into and forcing the medication from the ampule; a syringe drive mechanism for providing power to drive the syringe plunger to force medication out of the syringe ampule, the drive mechanism operable to provide a first level force during a first, short period of injection, and a second, lower level of force during a second, longer period of injection, the second level of force being substantially constant for the second period of injection.
- Yet another aspect of the invention provides a needleless, compressed gas powered injector adapted to receive a syringe with medication therein.
- the injector includes a syringe drive system for providing compressed gas drive to the syringe mounted in the injector, and a pressure switch for determining whether the injector has sufficient compressed gas pressure, and for warning the user if there is insufficient pressure and for preventing initiation of the apparatus in the event of insufficient compressed gas pressure.
- a further aspect of the invention is a needleless injector adapted to receive a syringe with medication therein for injection, and using an elongated compressed gas cartridge which is pierceable at one end, the gas cartridge providing compressed gas to the injector, the injector including a cartridge access door which opens and closes, and the injector defining a cartridge receptacle for receiving the cartridge, the cartridge receptacle having a first end and a second end, the first end of which terminates in a piercing pin for piercing the cartridge, the second end of which terminates in a seat, with at least one of the piercing pin and the seat moving away from the other with the opening of the door and toward the other with the closing of the door, the piercing pin and the seat being positioned relative to each other and with respect to the size of the cartridge such that when the door is open, the receptacle is longer than the cartridge, and when the door is closed, the cartridge will be pierced.
- Another aspect of the invention is a needleless, compressed gas powered injector for injecting medication through a syringe, the injector including a dose adjustment mechanism interconnected with a dose compensator, the dose compensator defining a chamber which is enlarged and reduced in size as the amount of medication is reduced and increased, respectively, the dose compensator chamber receiving compressed gas when the injector injects medication.
- Fig. 1 is a perspective view of the exterior of a first embodiment of the present invention
- Fig. 2 is a side elevation view of the exterior of the embodiment of Fig. 1;
- Fig. 3 is a rear end view of the embodiment of Fig. 1, showing the indicator panel;
- Fig. 4 is a front end view of the embodiment of Fig. 1, showing the syringe collar and the skin sensor;
- Fig. 5 is an exploded view showing how the external parts of the embodiment of Fig. 1 fit together;
- Fig. 6 is a side elevation view of the C0 2 cartridge access door closure mechanism of the embodiment of Fig. 1;
- Fig. 7 is a top plan view of the C0 2 cartridge access door closure mechanism of the embodiment of Fig. 1;
- Fig. 8 is a side elevation sectional view of the embodiment of Fig. l;
- Fig. 8A is a fragmentary, enlarged view corresponding to Fig. 8, showing the solenoid valve components
- Fig. 8B is a view corresponding to Fig. 8, showing the syringe mounted in place in the apparatus;
- Fig. 9 is partially sectioned side elevation view of the dose adjustment mechanism of the embodiment of Fig. 1;
- Fig. 10 is a side elevation sectional view of the syringe to be used with the embodiment of Fig. 1;
- Fig. 11 is a side elevation sectional view of the pressure switch of the embodiment of Fig. 1;
- Fig. 12 is an enlarged view corresponding to that of Fig. 3;
- Fig. 13 is the logic circuit of the preferred embodiment of Fig. 1;
- Fig. 14 is a graphical depiction of the "syringe pressure vs. time" of the injection cycle.
- apparatus 2 includes a convenient molded plastic case, made up of a base portion 4, a pivotable cartridge access door 6, a slidable dose adjustment door 8, a syringe collar 9, a skin sensor 10, an indicator panel 11, an initiator switch 13, and a carrying strap 15.
- Fig. 5 depicts how these parts fit together to form an integral unit.
- apparatus 2 can be seen to include several basic components.
- a replaceable C0 2 cartridge 12 is disposed at one side of the apparatus, toward the front.
- a cartridge pressure control system is shown behind cartridge 12 at 14.
- a syringe 126 which is adapted to hold and then inject a predetermined amount of medication.
- a syringe control system 18 Positioned rearwardly of the syringe is a syringe control system 18 which controls activation of the syringe.
- the syringe control system 18 is in turn controlled from pressure which is provided by the cartridge pressure control system 14.
- Indicator panel 11 is disposed at the rear end of the apparatus, and it includes a power button 171 to activate the apparatus and a series of indicator lamps to keep the operator advised of the condition of the apparatus.
- Skin sensor 10 is disposed at the front end of the apparatus, and is used to prevent initiation of the injection process unless the skin sensor is depressed an appropriate amount as the apparatus is pressed against the skin of the patient.
- a pair of 1.5 volt AAA batteries 26 are mounted in a battery casing 146 disposed between C0 2 cartridge 12 and syringe 126 to provide power for the apparatus logic circuit, warning lights, etc.
- the C0 2 cartridge 12 is typically a 33 gram steel cartridge of conventional design, holding 8 grams of C0 2 . This is usually enough for approximately 6-8 injections, although if the apparatus is used infrequently, passive gas leaks may result in fewer injections per cartridge.
- C0 cartridge 12 is positioned within a cartridge receptacle 28 between a forward seat 30 which is curved to complement the curvature of the forward, rounded portion of the cartridge, and a rear area having a resilient cartridge sealing gasket 34. This gasket is sized and positioned such that a piercing pin 36 is adapted to extend through an annulus at the axial center of the gasket in order to pierce the rear end of the cartridge 12 to release C0 2 pressure upon closure of hinged cartridge access door 6.
- hinged cartridge access door 6 is mounted to the ends of a pair of roughly Z-shaped cartridge door closure arms 44 by a pair of small bolts 39 which slide in slots 35 as the door is opened and closed.
- Cartridge access door 6 is mounted to a so-called pierce block frame 41 and a pierce block 42 by closure arms 44 which straddle the pierce block and are pivotally connected to the pierce block frame at pivot points 43.
- Pivot points 43 actually are in the form of rivets, and to ensure that the pierce block travels parallel to the pierce block frame, a slot (not shown) extends along each side of the pierce block, and the inner portion of the rivet thereby guides the travel of the pierce block.
- Closure arms 44 are also pivotally mounted to a pair of pivotal legs 50 disposed to each side of pierce block frame 41 at pivot points 48.
- the opposite ends of legs 50 pivotally connect to a pierce block pin 46 which extends through and is mounted to pierce block 42.
- Pivotable legs 50 each include a bend at their mid-portions as shown in Fig. 7 to accommodate the length of closure arms 44.
- Pierce block pin 46 is mounted to reciprocate in a pair of forked ends 45 in pierce block frame 41 as cartridge access door 6 is opened and closed and pierce block 42 is shifted forwardly and rearwardly.
- legs 50 convey the motion of closure arms 44 to pierce block pin 46 and to pierce block 42 which shifts within pierce block frame 41.
- This causes forward seat 30 to exert a rearward force (to the left in Figs. 6, 7 and 8) on C0 2 cartridge 12.
- this causes piercing pin 36 to pierce the rear end of cartridge 12.
- a series of 17 so-called belleville spring washers 52 are disposed in series between forward seat 30 and pierce block 42 to provide a predetermined piercing pressure of slightly over 100 pounds, which is maintained the entire time cartridge access door 6 is closed.
- pressurized C0 gas passes from the cartridge through piercing pin 36, and as best shown in Fig. 8A, to a solenoid valve 54 through a (.25 x 118" 2 micron) gas filter 56 and through a conduit 58 extending through the axial center thereof.
- a space 60 extending entirely across solenoid valve 54 thus is filled with pressurized gas, as is an axially centered spring chamber 62 in which a solenoid spring 64 is disposed.
- Solenoid spring 64 holds a resilient solenoid seal 66 against a solenoid seat 68 to prevent the flow of pressure into an axially extending rear conduit 59.
- a pair of O-rings 70 are mounted in the solenoid valve to prevent flow of pressurized gas along the interior wall 72 of the pressure control system 14.
- a circumferential ring 74 extends entirely around solenoid valve 54 to ensure that the solenoid valve remains stationary in the pressure control system 14.
- a generally cylindrical piston 76 is disposed between space 60 and solenoid seal 66.
- piston 76 in combination with solenoid seal 66, acts as to control the flow of gas pressure through solenoid valve 54.
- a sleeve 61 fits around the piston, and well past space 60, and an 0-ring 63 prevents C0 2 pressure from passing forwardly along the sleeve. Pressure is, however, able to pass rearwardly along the interface between the sleeve and the piston because another O-ring 65, disposed rearwardly of space 60, is positioned outwardly of the sleeve.
- the cartridge pressure control system 14 also includes a poppet valve 80 (see Fig. 8) having a resilient poppet valve seal 82 which bumps up against rear conduit 59 to create a shuttling phenomenon when the poppet valve shifts forwardly or to the right, as will be described later in this discussion.
- Poppet valve 80 includes a radially extending port 86 which interconnects the inner portion of the poppet valve with a gas reservoir 84. Prior to the point that the reservoir is subjected to C0 2 pressure, poppet valve 80 will be in the position depicted in Fig. 8.
- a poppet valve spring 88 holds the poppet valve in the depicted position, with a poppet valve seat 90 disposed against the poppet valve to close the poppet valve.
- pressurized C0 2 flows through piercing pin 36 and filter 56 (see Fig. 8A). It is directed through conduit 58 and into space 60 and spring chamber 62, and along the interface between sleeve 61 and piston 76 to the rear of the piston. While the pressure is therefore equalized at the two ends of the piston, because the surface area is greater on the front side of the piston if the surface area of solenoid seal 66 is included, the piston will remain in the position shown in Figs. 8 and 8A, with the solenoid seal seated firmly against solenoid seat 68, thereby preventing pressure from entering reservoir 84.
- solenoid valve 54 is shifted slightly (approximately .012 inch) forward or to the right in Figs. 8 and 8A, but not so far as to close off space 60.
- This enables pressurized gas to flow through rear conduit 59 into gas reservoir 84.
- pressurized C0 2 flows through port 86 in poppet valve 80 (see Fig. 8).
- the poppet valve lifts off its seat 90, permitting pressure to rush into the next section of the apparatus.
- the poppet valve is normally set to lift off of its seat at a pressure of 480 psi.
- the initial rush of C0 pressure provides a syringe pressure of approximately 3920 psi to penetrate the patient's skin, followed by a sustained, substantially constant pressure of approximately 1700 psi for about 0.5 seconds during the shuttling phase.
- substantially constant as used herein is intended to encompass a variation of from about 2000 psi to 1600 psi as shown in Fig. 14 between the 0.1 and 0.56 second points of the injection cycle. This pressure profile has been found to be superior to some prior art pressure profiles which peak quickly but then drop off sharply.
- a threaded poppet valve pressure adjustment face 91 may be threaded inwardly to increase or outwardly to decrease the pressure at which poppet valve 80 opens and closes.
- a special tool (not shown) is used to facilitate this adjustment.
- syringe control system 18 which receives C0 2 pressure from poppet valve 80, will now be described.
- This system includes a dose compensator cylinder 94, a dose variation assembly 96 having a pressure piston 98 mounted thereto, an inner cylinder 100, a rearward outer cylinder 102, and a forward outer cylinder 104. So-called U-cup seals 99 and 101 will prevent pressure leakage between the stages of the syringe control system.
- the C0 pressure entering the syringe control system 18 causes the entire rearward outer cylinder 102 to shift forwardly or to the right in Fig. 8, against the compressive action of a light helical spring 97.
- Rearward outer cylinder 102 continues to shift until its forward end contacts the rear end of forward outer cylinder 104, which is about 1/8 - 3/16 inch into its travel.
- inner cylinder 100 continues to move in a forward direction for approximately another 1 - V ⁇ inch, for a total travel of approximately V ⁇ inches.
- This independent movement of the inner cylinder generally corresponds with the point that the shuttling begins in the cartridge pressure control system 14.
- the independent movement of inner cylinder 100 cooperates with the shuttling action to provide a reduced, substantially constant but lower second pressure phase to the injector.
- spring 97 will have bottomed out and immediately thereafter the controller will cause the solenoid valve to shut off C0 2 pressure.
- Dose compensator cylinder 94 travels with inner cylinder 100 and rearward outer cylinder 102 in their above-described forward motion.
- Dose compensator cylinder 94 is a generally cylindrical member having a soft rubber bumper at the rear end thereof (not shown due to its small dimensions), and a centrally disposed axially extending channel 108 with an entry segment 110 at the rear end thereof, as shown best in Fig. 8. This entry segment 110 selectively interconnects channel 108 with fluid pressure from poppet valve 80.
- An O-ring 112 is provided on dose compensator cylinder 94 to prevent the flow of fluid pressure along the outer surface of the cylinder.
- a seal 114 is provided at the forward end of the dose compensator cylinder to minimize any leakage between the inner cylinder wall defining channel 108 and pressure piston 98.
- the purpose of the dose compensator cylinder system is to account for the fact that pressure will tend to act somewhat differently on the syringe control system 18 when there is a greater or lesser amount of medication in the syringe. Because pressure piston 98 will move forwardly and rearwardly within channel 108 as the dosage is decreased and increased, respectively, thereby increasing and decreasing, respectively, the size of a chamber defined within channel 108 behind piston 98, this accommodation is made.
- a helical spring 115 is positioned between dose compensator cylinder
- Dose indicator flag 106 is mounted to a cylindrical dose variation compensator 120 so that the position of the flag generally corresponds to the amount of medication in the syringe.
- flag 106 will block infrared light from passing across space 107 from an illuminator (not shown) to a receptor (not shown).
- spring 115 will cause flag 106 to be shifted to the right, withdrawing the flag from space 107 and permitting IR light to pass from the illuminator to the receptor, which will send a signal to the controller, thereby lighting a warning lamp and preventing the apparatus from entering its initiation phase.
- Dose variation assembly 96 permits the dosage to easily be adjusted in l A cc increments (see Fig. 9). This is done through the use of a thumb-nail manipulator 118 which extends radially outwardly from the unit and which is mounted by a lock nut 111 to an axially extending rod 113 which is threaded into dose variation compensator 120.
- the dose variation compensator has a generally semi-spherical protrusion 122 mounted on it, and it is surrounded by a cylindrical jacket 123 shown best in Fig. 9.
- This jacket 123 has four circumferentially extending slots 125 interconnected by a single axially extending slot 127, the four slots being adapted to selectively receive semi- circular protrusion 122.
- Partitions 124 are disposed between and define the four slots.
- Fig. 9 shows that the partitions are relatively narrow in their circumferential dimensions, so that with only a 40-45° twist of compensator 120 with thumbnail manipulator 118, semi-spherical protrusion 122 can clear the adjacent partition, and under the pressure from springs 115, will be biased forwardly through axially extending slot 127 into the next adjacent slot 125, thereby adjusting the dosage by ! ⁇ cc.
- the protrusion can selectively be guided over to another one of the four slots, depending upon the desired dosage. Once positioned, releasing the thumbnail manipulator permits a series of rotational biasing springs 119 to cause dose variation compensator 120 to rotate, which in turn moves the protrusion into one of the four slots 125.
- the syringe 126 is shown best in Fig. 10. It includes an ampule 128 and a plunger 130.
- the end of the plunger includes a radially extending notch 132 which is interconnected with an axial slot 127 which is sized to fit onto rod 113 extending from dose variation compensator 120.
- a flared end 134 on the plunger is designed to abut the forward end of dose variation compensator 120.
- the syringe also includes a pair of opposed flanges 129 disposed adjacent the forward end thereof.
- the syringe ampule 128 includes a small injection aperture 20 at the forward end. Aperture 20 is typically 0.0045 inch in diameter, although it may be as large as 0.014 inch, depending upon the subcutaneous injection depth which is desired.
- Syringe 126 fits into the apparatus by merely inserting the syringe through collar 9 in the front end of the apparatus, and pushing it in. When it is most of the way in, pressure from spring 115 will be felt. When it bottoms out against a wave spring 131, the syringe is rotated approximately 90 degrees so that flanges 129 are engaged within the syringe collar 9 as shown in Fig. 8B. As the syringe is rotated that 90 degrees, it engages a pin 133 which rotates with it. Once this pin 133 is rotated, it depresses a syringe lock micro switch 140, which sends a signal to the controller that the syringe has been properly installed. If this syringe lock micro switch is not depressed, the controller will light a warning lamp and prevent the apparatus from entering its initiation phase.
- a pressure switch 148 is disposed midway between and to the side of the portions of the apparatus which house the cartridge pressure control system 14 and the syringe control system 18, as shown best in Fig. 5.
- pressure switch 148 includes a bellows 150, a spring 152 and a central rod 154 which terminates in a flag 156.
- Flag 156 is disposed within a stationary optical interrupter 158 which transmits infrared light across a space 160 much like the previously-described dose measurement optical interrupter. When the flag is disposed within the space, the light is interrupted and a collector (not shown), which otherwise receives light from an emitter (not shown), sends a signal to a controller.
- Bellows 150 is subjected to C0 2 cartridge pressure because a port 151 interconnects an otherwise-sealed chamber 162 surrounding the bellows with the C0 2 pressure present within solenoid valve 54.
- the variations in pressure cause the bellows to expand and contract, causing rod 154 and flag 156 to move slightly forwardly and rearwardly in relation to optical interrupter 158.
- a pin 155 travels within a short slot 157 such that some contraction or expansion of the bellows is permitted without causing any displacement of flag 156.
- the flag blocks the transmission of IR light across space 160, but if the pressure is not as high as it should be, spring 152 causes bellows 150 to extend slightly into chamber 162, thereby causing rod 154 to withdraw flag 156 from optical interrupter 158, permitting IR light to be conveyed to a collector. This sends a signal to the controller, which lights an appropriate warning lamp and terminates the initiation cycle.
- a pressure switch other than the above- described bellows/optical interrupter could be used.
- a pressure switch other than the above- described bellows/optical interrupter could be used.
- a helical or a spiral bourdon tube could be used in place of the bellows, and another type of switch other than the described optical interrupter.
- skin sensor 10 is provided.
- the skin sensor includes an extension rod 142 which is forwardly biased under the pressure of a skin sensor spring 144 to the extended position shown in Fig. 8.
- a soft plastic jacket 138 fits over the extension rod in the depicted embodiment.
- the extension rod is depressed against the pressure of the skin sensor spring, and a spring sensor micro switch 144 is contacted, sending an electronic signal to the controller to prevent termination of the initiation cycle. If the skin sensor is not sufficiently depressed, the controller lights a warning lamp and the initiation cycle is terminated.
- Skin sensor 10 thereby functions to prevent inadvertent or other discharge of the apparatus when the apparatus is not properly positioned against the skin, which may happen if the patient is reluctant or, again, physical dexterity problems make it difficult for the patient to properly position the apparatus.
- Indicator panel 11 shown best in Fig. 12, includes the following red warning lamps: C0 2 pressure warning lamp 184; dose volume warning lamp 194; syringe lock warning lamp 191; and battery warning lamp 176.
- a green "ready" lamp 200 is also included, as is a power button 171.
- control circuit schematic Fig. 13, as well as to the indicator panel 11 provided at the rear of the apparatus, and depicted in Fig. 12.
- the logic circuit indicated generally with the numeral 164, selectively provides power to light the lamps of the indicator panel.
- controller 166 Central to the circuit is controller 166 which in the preferred embodiment is an Atmel programmable logic device, designated as model ATF 1500L. This is a low power unit which can effectively control the operation of the apparatus while using a minimal amount of power so that the batteries do not have to be replaced very often.
- the apparatus includes a number of interlocks which prevent the unit from operating, and warn the operator in the event any one of a number of conditions is not satisfied.
- the logic circuit provides this capability, but before describing those features, reference will first be made to the general layout of the circuit.
- the batteries, shown at 26, are mounted in series to provide 3 volts of DC power to the circuit.
- a power switch 170 which corresponds with power button 171 (see Fig. 12), controls the flow of power to a DC-DC converter 172, which converts the 3 volt charge to a 5 volt charge as needed elsewhere in the circuit.
- a signal is sent to the controller via line 174, and a red "battery" light 176 is activated in indicator panel 11 depicted in Fig. 12.
- This light is energized by an LED 178 which is connected to an active low pin in controller 166 which sends the 3 volt charge to ground upon a low battery signal from line 174, thereby energizing the LED and warning the operator that the batteries need to be replaced. This event prevents the initiation of the apparatus so that even if the operator ignores the light, the apparatus cannot be initiated. In the event there is sufficient battery power, voltage is provided to the controller to activate the apparatus.
- pressure switch 148 determines whether sufficient C0 2 pressure is sufficient. If it is, flag 156 will block light from passing through optical interrupter 158, and a transistor in a C0 2 detect subcircuit 180 will remain open. In this condition, the controller will sense the 5 volt charge coming in from line 181. If C0 2 pressure is insufficient, the flag will withdraw, permitting light to pass through the optical interrupter, which will then close the C0 2 detect subcircuit 180, thus grounding the 5 volt charge, which will be sensed by the controller.
- an active low pin to which a C0 2 cartridge LED 182 is connected will ground that LED circuit, energizing that LED and activating a red C0 2 cartridge light 184 in indicator panel 11, as shown in Fig. 12. This event also causes the controller to prevent initiation of the apparatus even if the user ignores the indicator panel warning light 184.
- a dose detect subcircuit 190 very similar to C0 2 detect subcircuit 180, is provided. Dose detect subcircuit 190 is provided with a 5 volt charge from line 181, and if a sufficient dosage level is sensed by the dose indicator optical interrupter, a transistor in the dose detector subcircuit will remain open and the controller will sense 5 volts. If the dose is insufficient, the transistor will close and the controller will sense the absence of the 5 volt charge. In that event, a red volume warning lamp 194 is lit in indicator panel 11 by a dose detector LED 192. This light is connected to an active low pin in the controller which sends the 3 volt charge to ground, thereby activating the LED. Unless the dose is sufficient, this dose interlock will warn the user at the indicator panel and will prevent the apparatus from initiating.
- a syringe switch 186 which ensures that the syringe is properly locked into positioned in the apparatus before the unit is initiated. As noted previously, this condition is sensed by syringe lock micro switch 140. Syringe switch 186 receives a 5 volt charge from line 188. If the syringe is properly locked in place, the syringe switch will be closed. In this condition, the controller senses the 5 volt charge, and the apparatus is ready for initiation. If the syringe is not properly locked in place, a syringe lock LED 193 will activate a red syringe lock warning lamp 191 and the controller will prevent the apparatus from entering its initiation cycle. If all of the conditions have been met (other than the next-to-be- described skin sensor), the controller operates to flash a green "ready" light 200 in indicator panel 11.
- a skin sensor switch 196 is provided off 5 volt line 181.
- skin sensor 10 In order to initiate the apparatus, skin sensor 10 must be depressed, thereby closing skin sensor switch 196 and sending a 5 volt charge to the controller. Unless this charge is sensed by the controller, the apparatus will be prevented from entering its initiation cycle.
- skin sensor LED 198 When the charge is received, showing that everything is ready for initiation, skin sensor LED 198 will provide a steady activation of the green "ready" light 200 in indicator panel 11, and an audible indicator 202 will emit a beep.
- An initiator switch 204 is also provided off 5 volt line 181, which is closed by depressing indicator panel initiator button 171. If all of the foregoing conditions have been satisfied, closing of the initiator switch will send a 5 volt charge to the controller, which in turn sends power to solenoid valve 54 to cause C0 2 pressure to inject medication into the patient. If any of the foregoing conditions have not been satisfied, the appropriate warning lights will be lit, and the controller will prevent the apparatus from entering its initiation cycle.
- the user first must install batteries 26 into battery case 146. This is done by opening cartridge access door 6 and removing the C0 2 cartridge if there is one in place.
- C0 2 cartridge 12 is installed into cartridge receptacle 28. Once the cartridge is in place, cartridge access door 6 is pivoted closed. The action of the cartridge door mechanism causes pierce block 42 to shift rearwardly and under the action of springs 52, forward seat 30 pushes rearwardly on the cartridge, which causes the rear of the cartridge to be pushed down so that piercing pin 36 pierces the rear end of the cartridge.
- the batteries should last for an extended period, and the C0 2 cartridge will last for approximately 6 to 8 injections.
- the dose adjust mechanism is set, and the syringe is filled with medication and placed into the apparatus.
- thumbnail manipulator 118 is adjusted to the appropriate dosage by first sliding open the dose adjustment door 8, and then turning the manipulator slightly and moving it axially to the right to decrease and to the left to increase the dosage, in V ⁇ CC increments. The dose adjustment door is then closed and the apparatus is ready to receive the syringe.
- the syringe 126 is first filled with the desired amount of medication, is purged of air and is then mounted in the apparatus.
- the syringe is normally over-filled so that there is somewhat more medication in the ampule than the apparatus dosage setting, just to make sure the ampule is not underfilled.
- the apparatus is now ready to have the power turned on, so this is done by depressing power button 171 on indicator panel 148. Once the power is on, the operator can check to see if C0 2 pressure warning lamp 184 is lit, and if it is, then the pressure switch 148 has determined that there is insufficient pressure, and the C0 2 cartridge needs to be replaced. Similarly, if the syringe has not been properly installed, the red syringe lock lamp 191 on the indicator panel will be lit; if there is insufficient medication in the syringe as determined by the dose indicator, the red dose volume lamp 194 will be lit; and if there is insufficient battery power, the red battery warning lamp 176 will be lit.
- the apparatus is ready for use, and the green "ready” light 200 will flash intermittently.
- the user presses the front end of the apparatus against the skin, which depresses skin sensor 10. This causes the green "ready” lamp 200 on the indicator panel to light, and the audible alarm to sound, informing the user that the apparatus is ready to initiate.
- Depression of initiator button 171 causes the initiator switch to close if all four of the aforementioned conditions are met. This in turn activates solenoid valve 54 which permits pressurized C0 2 to rush into gas reservoir 84, causing poppet valve 80 to lift, sending pressure into the syringe control side of the apparatus.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU72549/98A AU7254998A (en) | 1997-05-19 | 1998-04-22 | Injection apparatus |
EP98919849A EP1011763B1 (en) | 1997-05-19 | 1998-04-22 | Injection apparatus |
DE69820460T DE69820460T2 (en) | 1997-05-19 | 1998-04-22 | INJECTION DEVICE |
CA002290777A CA2290777C (en) | 1997-05-19 | 1998-04-22 | Injection apparatus |
GBGB9927246.0A GB9927246D0 (en) | 1997-05-19 | 1999-11-18 | Injection apparatus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/858,249 US5993412A (en) | 1997-05-19 | 1997-05-19 | Injection apparatus |
US08/858,249 | 1997-05-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998052632A1 true WO1998052632A1 (en) | 1998-11-26 |
Family
ID=25327861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/008161 WO1998052632A1 (en) | 1997-05-19 | 1998-04-22 | Injection apparatus |
Country Status (7)
Country | Link |
---|---|
US (1) | US5993412A (en) |
EP (1) | EP1011763B1 (en) |
AU (1) | AU7254998A (en) |
CA (1) | CA2290777C (en) |
DE (1) | DE69820460T2 (en) |
GB (1) | GB9927246D0 (en) |
WO (1) | WO1998052632A1 (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6607510B2 (en) | 2001-11-09 | 2003-08-19 | Bioject Medical Technologies Inc. | Disposable needle-free injection apparatus and method |
US6676630B2 (en) | 2002-06-04 | 2004-01-13 | Bioject Medical Technologies, Inc. | Needle-free injection system |
US6883222B2 (en) | 2002-10-16 | 2005-04-26 | Bioject Inc. | Drug cartridge assembly and method of manufacture |
US7615645B2 (en) | 2003-10-21 | 2009-11-10 | Basf Aktiengesellschaft | Method for the continuous production of aldehydes |
USRE43824E1 (en) | 2001-01-11 | 2012-11-20 | Powder Pharmaceuticals Inc. | Needleless syringe |
EP2537546A1 (en) * | 2011-06-21 | 2012-12-26 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device with dose control mechanism |
US9022980B2 (en) | 2005-02-01 | 2015-05-05 | Kaleo, Inc. | Medical injector simulation device |
US9022022B2 (en) | 2011-02-28 | 2015-05-05 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9044546B2 (en) | 2007-05-04 | 2015-06-02 | Powder Pharmaceuticals Incorporated | Particle cassettes and processes therefor |
US9056170B2 (en) | 2004-11-22 | 2015-06-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9149579B2 (en) | 2004-11-22 | 2015-10-06 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9238108B2 (en) | 2005-02-01 | 2016-01-19 | Kaleo, Inc. | Medicament delivery device having an electronic circuit system |
US9259539B2 (en) | 2005-02-01 | 2016-02-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9278177B2 (en) | 2005-02-01 | 2016-03-08 | Kaleo, Inc. | Medical injector with compliance tracking and monitoring |
US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
US9522235B2 (en) | 2012-05-22 | 2016-12-20 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
US9542826B2 (en) | 2012-12-27 | 2017-01-10 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
US9555191B2 (en) | 2007-01-22 | 2017-01-31 | Kaleo, Inc. | Apparatus and methods for self-administration of vaccines and other medicaments |
US9724471B2 (en) | 2005-02-01 | 2017-08-08 | Kaleo, Inc. | Devices, systems, and methods for medicament delivery |
US9814838B2 (en) | 2011-01-26 | 2017-11-14 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9833573B2 (en) | 2004-11-22 | 2017-12-05 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
WO2019005072A1 (en) * | 2017-06-29 | 2019-01-03 | Regeneron Pharmaceuticals Inc. | Devices and methods for overfilling drug containers |
US10192464B2 (en) | 2008-07-28 | 2019-01-29 | Kaleo, Inc. | Medicament delivery device configured to produce wireless and audible outputs |
US10238806B2 (en) | 2011-01-26 | 2019-03-26 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
US10332623B2 (en) | 2017-01-17 | 2019-06-25 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and event detection |
US10576206B2 (en) | 2015-06-30 | 2020-03-03 | Kaleo, Inc. | Auto-injectors for administration of a medicament within a prefilled syringe |
US10688244B2 (en) | 2016-12-23 | 2020-06-23 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
US10695495B2 (en) | 2015-03-24 | 2020-06-30 | Kaleo, Inc. | Devices and methods for delivering a lyophilized medicament |
US10737028B2 (en) | 2004-11-22 | 2020-08-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US11167087B2 (en) | 2019-08-09 | 2021-11-09 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
US11590286B2 (en) | 2004-11-22 | 2023-02-28 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
USD994111S1 (en) | 2008-05-12 | 2023-08-01 | Kaleo, Inc. | Medicament delivery device cover |
US11929160B2 (en) | 2018-07-16 | 2024-03-12 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and compliance detection |
Families Citing this family (450)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6156008A (en) * | 1998-05-04 | 2000-12-05 | Castellano; Thomas P. | Device for avoiding subdermal hematomas from an injection |
US6129361A (en) * | 1998-07-06 | 2000-10-10 | Ford Global Technologies, Inc. | Fluid conduit seal |
US6315777B1 (en) * | 1998-07-07 | 2001-11-13 | Medtronic, Inc. | Method and apparatus for creating a virtual electrode used for the ablation of tissue |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US6783509B1 (en) | 1998-11-18 | 2004-08-31 | Bioject Inc. | Single-use needle-less hypodermic jet injection apparatus and method |
WO2000030704A1 (en) * | 1998-11-24 | 2000-06-02 | Pickrell Marc R | Improved multi-dose non-needle jet injection device |
US6406455B1 (en) * | 1998-12-18 | 2002-06-18 | Biovalve Technologies, Inc. | Injection devices |
US7060048B1 (en) * | 1999-04-16 | 2006-06-13 | Powerject Research Limited | Needleless syringe |
US6689095B1 (en) | 1999-04-22 | 2004-02-10 | Gilbert Garitano | Needleless permanent makeup and tattoo device |
US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US6319224B1 (en) * | 1999-08-20 | 2001-11-20 | Bioject Medical Technologies Inc. | Intradermal injection system for injecting DNA-based injectables into humans |
US20050027239A1 (en) * | 1999-08-20 | 2005-02-03 | Stout Richard R. | Intradermal injection system for injecting DNA-based injectables into humans |
US6569143B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Method of intradermally injecting substances |
US20020193740A1 (en) | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
US6843781B2 (en) * | 1999-10-14 | 2005-01-18 | Becton, Dickinson And Company | Intradermal needle |
US6776776B2 (en) * | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
US6569123B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Prefillable intradermal injector |
EP1296730B2 (en) * | 2000-01-07 | 2014-07-30 | Valeritas, Inc. | Injection device |
IL151097A0 (en) | 2000-02-23 | 2003-04-10 | Smithkline Beecham Biolog | Tumour-specific animal proteins |
US6689131B2 (en) | 2001-03-08 | 2004-02-10 | Tissuelink Medical, Inc. | Electrosurgical device having a tissue reduction sensor |
ES2643763T3 (en) | 2000-03-06 | 2017-11-24 | Salient Surgical Technologies, Inc. | Fluid supply system and controller for electrosurgical devices |
US8048070B2 (en) | 2000-03-06 | 2011-11-01 | Salient Surgical Technologies, Inc. | Fluid-assisted medical devices, systems and methods |
US6558385B1 (en) | 2000-09-22 | 2003-05-06 | Tissuelink Medical, Inc. | Fluid-assisted medical device |
WO2003024349A1 (en) | 2001-09-05 | 2003-03-27 | Tissuelink Medical, Inc. | Fluid-assisted medical devices, systems and methods |
US7811282B2 (en) | 2000-03-06 | 2010-10-12 | Salient Surgical Technologies, Inc. | Fluid-assisted electrosurgical devices, electrosurgical unit with pump and methods of use thereof |
US6645169B1 (en) * | 2000-06-08 | 2003-11-11 | Avant Drug Delivery Systems, Inc. | Air-in-tip jet injector |
JP2004513615A (en) | 2000-06-28 | 2004-05-13 | コリクサ コーポレイション | Compositions and methods for treatment and diagnosis of lung cancer |
US6440096B1 (en) * | 2000-07-14 | 2002-08-27 | Becton, Dickinson And Co. | Microdevice and method of manufacturing a microdevice |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
PT1889630E (en) | 2000-10-18 | 2012-02-29 | Glaxosmithkline Biolog Sa | Vaccines comprising mage antigen linked to protein d fragment |
US6652483B2 (en) * | 2000-11-07 | 2003-11-25 | Avant Drug Delivery Systems, Inc. | Needleless jet injector system with separate drug reservoir |
US7931614B2 (en) | 2000-11-30 | 2011-04-26 | Valeritas, Inc. | Injection systems |
GB2371754B (en) * | 2001-02-02 | 2005-09-21 | Biocompatibles Ltd | Balloon catheter inflation |
DE60239594D1 (en) | 2001-02-23 | 2011-05-12 | Glaxosmithkline Biolog Sa | INFLUENZA VACCINE COMPOSITIONS FOR INTRADERMAL ADMINISTRATION |
US6645170B2 (en) * | 2001-03-05 | 2003-11-11 | Bioject Medical Technologies, Inc. | Simplified disposable needle-free injection apparatus and method |
US6471669B2 (en) | 2001-03-05 | 2002-10-29 | Bioject Medical Technologies Inc. | Disposable needle-free injection apparatus and method |
JP2002263106A (en) * | 2001-03-12 | 2002-09-17 | Olympus Optical Co Ltd | Optical probe device |
JP2004529754A (en) | 2001-03-14 | 2004-09-30 | ペンジェット・コーポレーション | System and method for removing dissolved gases from a solution |
ZA200200808B (en) * | 2001-03-22 | 2002-08-12 | Roche Diagnostics Gmbh | Needleless hypodermic injection system, application device and medication cartridge therefor. |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
US6613010B2 (en) | 2001-04-13 | 2003-09-02 | Penjet Corporation | Modular gas-pressured needle-less injector |
WO2002087663A2 (en) | 2001-04-27 | 2002-11-07 | Penjet Corporation | Method and apparatus for filling or refilling a needle-less injector |
WO2002089747A2 (en) | 2001-05-09 | 2002-11-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
US20100221284A1 (en) | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
US20060018877A1 (en) * | 2001-06-29 | 2006-01-26 | Mikszta John A | Intradermal delivery of vacccines and therapeutic agents |
CN1253220C (en) | 2001-06-29 | 2006-04-26 | 贝克顿迪肯森公司 | Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
US7767872B2 (en) * | 2001-09-06 | 2010-08-03 | Mpg Biotechnologies, Llc | Thimerosal removal device |
US8440791B2 (en) * | 2001-09-06 | 2013-05-14 | Mgp Biotechnologies, Llc | Thimerosal removal device |
HUP0402259A3 (en) | 2001-09-20 | 2010-01-28 | Glaxo Group Ltd | Vaccines |
US6824526B2 (en) | 2001-10-22 | 2004-11-30 | Penjet Corporation | Engine and diffuser for use with a needle-less injector |
CA2476755C (en) | 2001-12-17 | 2014-08-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
US6551314B1 (en) | 2002-04-03 | 2003-04-22 | Thomas J. Fogarty | Methods and systems for vein harvesting |
US7074220B2 (en) * | 2002-04-03 | 2006-07-11 | Thomas J. Fogarty | Methods and systems for vein harvesting and fistula creation |
US20040049208A1 (en) * | 2002-04-03 | 2004-03-11 | Thomas Fogarty, M.D. | Methods and systems for vein harvesting and fistula creation |
US7156823B2 (en) * | 2002-06-04 | 2007-01-02 | Bioject Inc. | High workload needle-free injection system |
US7238167B2 (en) * | 2002-06-04 | 2007-07-03 | Bioject Inc. | Needle-free injection system |
JP2006504472A (en) | 2002-10-29 | 2006-02-09 | ティシューリンク・メディカル・インコーポレーテッド | Fluid-assisted electrosurgical scissors and method |
US20040143213A1 (en) * | 2002-11-12 | 2004-07-22 | Collegium Pharmaceutical, Inc. | Inertial drug delivery system |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
RU2389732C2 (en) | 2003-01-06 | 2010-05-20 | Корикса Корпорейшн | Certain aminoalkyl glucosaminide phospahte derivatives and use thereof |
US6935384B2 (en) * | 2003-02-19 | 2005-08-30 | Bioject Inc. | Needle-free injection system |
US20060184101A1 (en) * | 2003-04-21 | 2006-08-17 | Ravi Srinivasan | Microjet devices and methods for drug delivery |
JP2006524120A (en) * | 2003-04-21 | 2006-10-26 | ストラテージェント ライフ サイエンシズ | Apparatus and method for repetitively delivering drug by microjet |
IL155967A0 (en) * | 2003-05-18 | 2003-12-23 | Menachem Hartman | Automatic injector for mass injections |
AU2004272972A1 (en) | 2003-05-22 | 2005-03-24 | Fraunhofer Usa, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
EP1648931B1 (en) | 2003-07-21 | 2011-02-09 | Transgene S.A. | Multifunctional cytokines |
WO2005034949A1 (en) * | 2003-09-09 | 2005-04-21 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
US7727232B1 (en) | 2004-02-04 | 2010-06-01 | Salient Surgical Technologies, Inc. | Fluid-assisted medical devices and methods |
US7717874B2 (en) * | 2004-05-28 | 2010-05-18 | Bioject, Inc. | Needle-free injection system |
US20060005844A1 (en) * | 2004-07-08 | 2006-01-12 | Coulter George G | Rolling tube apparatus and method for treating a wound |
EP1793849A2 (en) | 2004-09-22 | 2007-06-13 | GlaxoSmithKline Biologicals SA | Immunogenic composition for use in vaccination against staphylococcei |
WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
JP4904283B2 (en) | 2004-12-01 | 2012-03-28 | アキュショット インク | Needleless syringe |
DE102004063650B4 (en) | 2004-12-31 | 2022-10-20 | Ypsomed Ag | Lifetime indicator for a product metering device |
JP2008529689A (en) | 2005-02-21 | 2008-08-07 | ノボ・ノルデイスク・エー/エス | Method of keeping the motor speed in the injection device constant |
PE20061428A1 (en) | 2005-03-23 | 2007-01-16 | Glaxosmithkline Biolog Sa | VACCINE FORMULATION INCLUDING AN OIL EMULSION ADJUVANT IN WATER AND 3D-MPL |
ES2732625T3 (en) | 2005-04-04 | 2019-11-25 | Univ Florida | Desferritiocin polyether analogs |
US7618393B2 (en) | 2005-05-03 | 2009-11-17 | Pharmajet, Inc. | Needle-less injector and method of fluid delivery |
US20070118093A1 (en) * | 2005-06-20 | 2007-05-24 | Von Muhlen Marcio G | High-speed jet devices for drug delivery |
EP1919504B1 (en) * | 2005-08-03 | 2013-10-16 | iBio, Inc. | Antibody to bacillus anthracis protective antigen |
US20070055199A1 (en) | 2005-08-10 | 2007-03-08 | Gilbert Scott J | Drug delivery device for buccal and aural applications and other areas of the body difficult to access |
US8202249B2 (en) * | 2005-09-20 | 2012-06-19 | Panasonic Corporation | Injection device with puncture function, method for controlling injection device with puncture function, chemical solution administration device, and method for controlling chemical solution administration device |
TWI457133B (en) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
WO2007070682A2 (en) | 2005-12-15 | 2007-06-21 | Massachusetts Institute Of Technology | System for screening particles |
US7988660B2 (en) * | 2005-12-20 | 2011-08-02 | Eli Lilly And Company | Needle-free injection device |
JO2813B1 (en) | 2005-12-22 | 2014-09-15 | جلاكسو سميث كلاين بايولوجيكالز اس.ايه | Pneumococcal polysaccharide conjugate vaccine |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
US20090081157A1 (en) | 2006-01-09 | 2009-03-26 | Richard Syd Kornbluth | Immunostimulatory Combinations for Vaccine Adjuvants |
JP2009526526A (en) * | 2006-02-13 | 2009-07-23 | フラウンホーファー ユーエスエー, インコーポレイテッド | Influenza antigens, vaccine compositions, and related methods |
US8277816B2 (en) * | 2006-02-13 | 2012-10-02 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
US20080279877A1 (en) * | 2006-02-13 | 2008-11-13 | Fraunhofer U.S.A. Inc. | HPV antigens, vaccine compositions, and related methods |
EP1998684A4 (en) * | 2006-03-10 | 2014-09-17 | Massachusetts Inst Technology | Triggered self-assembly conjugates and nanosystems |
US7666912B2 (en) | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
MX337528B (en) | 2006-03-30 | 2016-03-09 | Glaxosmithkline Biolog Sa | Immunogenic composition. |
ES2776100T3 (en) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | System for targeted delivery of therapeutic agents |
WO2007120638A2 (en) * | 2006-04-12 | 2007-10-25 | President And Fellows Of Harvard College | Methods and compositions for modulating glycosylation |
WO2007133807A2 (en) | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
WO2007143574A1 (en) * | 2006-06-02 | 2007-12-13 | President And Fellows Of Harvard College | Protein surface remodeling |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
SI2422810T1 (en) | 2006-07-17 | 2015-01-30 | Glaxosmithkline Biologicals S.A. | Influenza vaccine |
US7618396B2 (en) * | 2006-08-09 | 2009-11-17 | Avant Medical Corp. | Injection system with hidden needles |
US9115358B2 (en) | 2006-08-11 | 2015-08-25 | President And Fellows Of Harvard College | Moenomycin biosynthesis-related compositions and methods of use thereof |
KR20090050056A (en) * | 2006-08-14 | 2009-05-19 | 메사츄세츠 인스티튜트 어브 테크놀로지 | Hemagglutinin polypeptides, and reagents and methods |
US20090269342A1 (en) * | 2006-08-14 | 2009-10-29 | Massachusetts Institute Of Technology | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
US7942845B2 (en) * | 2006-09-19 | 2011-05-17 | Bioject, Inc. | Needle-free injector and process for providing serial injections |
US7547293B2 (en) | 2006-10-06 | 2009-06-16 | Bioject, Inc. | Triggering mechanism for needle-free injector |
JO3598B1 (en) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
BRPI0717219B8 (en) | 2006-10-12 | 2021-05-25 | Glaxosmithkline Biologicals Sa | immunogenic composition, and, use of an immunogenic composition |
EP2433648A3 (en) | 2006-10-12 | 2012-04-04 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
US8870821B2 (en) * | 2006-10-13 | 2014-10-28 | Michael D. Laufer | Device for tissue injection |
US7637889B2 (en) * | 2006-11-15 | 2009-12-29 | Glynntech, Inc. | Drug delivery device with sliding valve and methodology |
CN101848702B (en) | 2006-12-01 | 2013-07-17 | 安特里奥公司 | Amphiphilic entity nanoparticles |
WO2008073856A2 (en) * | 2006-12-08 | 2008-06-19 | Massachusetts Institute Of Technology | Delivery of nanoparticles and/or agents to cells |
US8011250B2 (en) * | 2006-12-22 | 2011-09-06 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Apparatus and method for controlling and monitoring the pressure in pressure line or pipes |
CN110003079A (en) | 2006-12-26 | 2019-07-12 | 兰休斯医疗成像公司 | For making the ligand of imaging cardiac innervation |
AU2008210434C8 (en) | 2007-01-31 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
WO2008103997A2 (en) | 2007-02-23 | 2008-08-28 | Bioject Inc. | Needle-free injection devices and drug delivery systems therefor |
AU2008229472B2 (en) | 2007-03-15 | 2013-03-14 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
BRPI0809366B8 (en) | 2007-03-28 | 2021-05-25 | Harvard College | substantially alpha-helical polypeptide, method for manufacturing same, amino acid and pharmaceutical composition |
JP2010523595A (en) | 2007-04-04 | 2010-07-15 | マサチューセッツ インスティテュート オブ テクノロジー | Poly (amino acid) targeting part |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
DE102007016811A1 (en) | 2007-04-05 | 2008-10-09 | Tecpharma Licensing Ag | Device for administering a fluid substance from a multi-chamber ampoule |
WO2008134643A2 (en) * | 2007-04-28 | 2008-11-06 | Fraunhofer Usa, Inc. | Trypanosoma antigens, vaccine compositions, and related methods |
WO2008137747A1 (en) | 2007-05-02 | 2008-11-13 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
CN101754770B (en) * | 2007-06-14 | 2015-05-20 | 克鲁塞尔瑞士股份公司 | Intradermal influenza vaccine |
WO2008156676A1 (en) | 2007-06-15 | 2008-12-24 | President And Fellows Of Harvard College | Methods and compositions for detecting and modulating o-glycosylation |
PT2167121E (en) | 2007-06-26 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
WO2009009759A2 (en) * | 2007-07-11 | 2009-01-15 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
WO2009046314A2 (en) * | 2007-10-04 | 2009-04-09 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
US10736848B2 (en) | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
EP2215269B1 (en) * | 2007-10-15 | 2017-12-13 | Admedus Vaccines Pty Limited | Construct system and uses therefor |
JP5067110B2 (en) * | 2007-10-17 | 2012-11-07 | マックス株式会社 | Gas fired driving tool |
US20090137949A1 (en) * | 2007-11-26 | 2009-05-28 | Bioject Inc. | Needle-free injection device with nozzle auto-disable |
US8617099B2 (en) * | 2007-11-26 | 2013-12-31 | Bioject Inc. | Injection device plunger auto-disable |
EP2227174B1 (en) | 2007-12-28 | 2019-05-01 | Salient Surgical Technologies, Inc. | Fluid-assisted electrosurgical device |
CN101951927A (en) * | 2008-01-03 | 2011-01-19 | 麻省理工学院 | Decoy influenza therapies |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
AR072249A1 (en) * | 2008-04-09 | 2010-08-18 | Infinity Pharmaceuticals Inc | INHIBITORS OF AMIDA HYDROLASS ACID FAT. APPLICATIONS. METHODS |
AU2009237647A1 (en) | 2008-04-16 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Vaccine |
AU2009243187C1 (en) * | 2008-04-28 | 2015-12-24 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
CA2724641C (en) * | 2008-05-20 | 2020-03-24 | Avant Medical Corp. | Autoinjector system |
US8052645B2 (en) | 2008-07-23 | 2011-11-08 | Avant Medical Corp. | System and method for an injection using a syringe needle |
BRPI0914630A2 (en) | 2008-06-26 | 2019-09-24 | Anterios Inc | dermal release |
JP5986745B2 (en) | 2008-07-15 | 2016-09-06 | アカデミア シニカAcademia Sinica | Glycan arrays on PTFE-like aluminum-coated glass slides and related methods |
AU2009274571A1 (en) * | 2008-07-23 | 2010-01-28 | Massachusetts Institute Of Technology | Activation of histone deacetylase 1 (HDAC1) protects against DNA damage and increases neuronal survival |
EP2356139A4 (en) | 2008-07-23 | 2013-01-09 | Harvard College | Ligation of stapled polypeptides |
DE102008048981A1 (en) * | 2008-09-25 | 2010-04-15 | Lts Lohmann Therapie-Systeme Ag | Injector and two-chamber system with sterile components |
WO2010036945A2 (en) * | 2008-09-26 | 2010-04-01 | The Regents Of The University Of Michigan | Nanoemulsion therapeutic compositions and methods of using the same |
WO2010037046A1 (en) | 2008-09-28 | 2010-04-01 | Fraunhofer Usa, Inc. | Humanized neuraminidase antibody and methods of use thereof |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
WO2010057197A1 (en) | 2008-11-17 | 2010-05-20 | The Regents Of The University Of Michigan | Cancer vaccine compositions and methods of using the same |
EP2376619A4 (en) | 2008-12-15 | 2012-07-04 | Greenlight Biosciences Inc | Methods for control of flux in metabolic pathways |
CN105132387A (en) * | 2008-12-22 | 2015-12-09 | 绿光生物科学公司 | Compositions and methods for the production of a compound |
US9254168B2 (en) | 2009-02-02 | 2016-02-09 | Medtronic Advanced Energy Llc | Electro-thermotherapy of tissue using penetrating microelectrode array |
EP2398416B1 (en) | 2009-02-23 | 2015-10-28 | Medtronic Advanced Energy LLC | Fluid-assisted electrosurgical device |
EP2416660B1 (en) | 2009-04-07 | 2014-07-02 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
AU2010234449A1 (en) | 2009-04-07 | 2011-11-03 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
US9221886B2 (en) | 2009-04-28 | 2015-12-29 | President And Fellows Of Harvard College | Supercharged proteins for cell penetration |
US9149465B2 (en) * | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US8927551B2 (en) * | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US8765735B2 (en) * | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
EP2438046A4 (en) | 2009-06-01 | 2013-04-17 | Harvard College | O-glcnac transferase inhibitors and uses thereof |
WO2010148111A1 (en) | 2009-06-16 | 2010-12-23 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
AU2010273220B2 (en) | 2009-07-13 | 2015-10-15 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
CN102497832B (en) | 2009-09-08 | 2015-09-09 | 显著外科技术公司 | For case assembly and the using method thereof of electro-surgical device, electrosurgical unit |
CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
EP2483307A1 (en) | 2009-09-29 | 2012-08-08 | Fraunhofer USA, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
CA2784807C (en) | 2009-12-29 | 2021-12-14 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
EP2528615B1 (en) | 2010-01-27 | 2020-05-13 | Massachusetts Institute of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
CN102834401B (en) | 2010-02-03 | 2016-08-24 | 无限药品股份有限公司 | Inhibitors of fatty acid amide hydrolase |
CN102844023B (en) | 2010-03-08 | 2016-01-20 | 索隆-基特林癌症研究协会 | CDC7 inhibitors of kinases with and uses thereof |
GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
US9592090B2 (en) | 2010-03-11 | 2017-03-14 | Medtronic Advanced Energy Llc | Bipolar electrosurgical cutter with position insensitive return electrode contact |
US9102697B2 (en) | 2010-03-22 | 2015-08-11 | President And Fellows Of Harvard College | Trioxacarcins and uses thereof |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
CA2736841C (en) | 2010-04-15 | 2014-02-18 | Teneo Innovations Inc. | Device and electronic controller for syringe piston control |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
WO2011140516A2 (en) | 2010-05-07 | 2011-11-10 | Greenlight Biosciences, Inc. | Methods for control of flux in metabolic pathways through enzyme relocation |
BR122020018186B1 (en) | 2010-05-11 | 2021-07-27 | Lantheus Medical Imaging, Inc | USE OF IMAGING AGENTS TO PREPARE A COMPOSITION FOR DETECTION OF THE NOREPINEPHRIN CONVEYOR (NET) AND METHOD FOR THE DETECTION OF NET |
US20110295249A1 (en) * | 2010-05-28 | 2011-12-01 | Salient Surgical Technologies, Inc. | Fluid-Assisted Electrosurgical Devices, and Methods of Manufacture Thereof |
US8658603B2 (en) | 2010-06-16 | 2014-02-25 | The Regents Of The University Of Michigan | Compositions and methods for inducing an immune response |
ES2664872T3 (en) | 2010-06-18 | 2018-04-23 | Taiho Pharmaceutical Co., Ltd | PRPK-TPRKB modulators and their uses |
US9138289B2 (en) | 2010-06-28 | 2015-09-22 | Medtronic Advanced Energy Llc | Electrode sheath for electrosurgical device |
US8906012B2 (en) | 2010-06-30 | 2014-12-09 | Medtronic Advanced Energy Llc | Electrosurgical devices with wire electrode |
US8920417B2 (en) | 2010-06-30 | 2014-12-30 | Medtronic Advanced Energy Llc | Electrosurgical devices and methods of use thereof |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
US8859723B2 (en) | 2010-08-13 | 2014-10-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US8916358B2 (en) | 2010-08-31 | 2014-12-23 | Greenlight Biosciences, Inc. | Methods for control of flux in metabolic pathways through protease manipulation |
EP2640405A4 (en) | 2010-09-21 | 2015-04-15 | Massachusetts Inst Technology | Human-adapted ha polypeptides, vaccines, and influenza treatment |
US8957026B2 (en) | 2010-09-22 | 2015-02-17 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AU2011312178B2 (en) | 2010-10-04 | 2016-05-12 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
US9023040B2 (en) | 2010-10-26 | 2015-05-05 | Medtronic Advanced Energy Llc | Electrosurgical cutting devices |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9089579B2 (en) | 2011-01-19 | 2015-07-28 | Topokine Therapeutics, Inc. | Methods and compositions for treating metabolic syndrome |
AU2012209274A1 (en) | 2011-01-24 | 2013-09-12 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
EP2667945A1 (en) | 2011-01-24 | 2013-12-04 | Anterios, Inc. | Oil compositions |
TR201905477T4 (en) | 2011-01-24 | 2019-05-21 | Anterios Inc | Nano-particle compositions. |
CN103889219A (en) | 2011-03-03 | 2014-06-25 | 特萨斯制药有限责任公司 | Compositions and methods comprising c16:1n7-palmitoleate |
GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
US9427281B2 (en) | 2011-03-11 | 2016-08-30 | Medtronic Advanced Energy Llc | Bronchoscope-compatible catheter provided with electrosurgical device |
WO2012135615A2 (en) | 2011-03-30 | 2012-10-04 | Brown University | Enopeptins, uses thereof, and methods of synthesis thereto |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US20140072622A1 (en) | 2011-05-17 | 2014-03-13 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
CN103796696B (en) * | 2011-05-25 | 2016-02-03 | 赛诺菲-安万特德国有限公司 | There is the agent delivery device of dispensing interface and control the method for this device |
TWI417120B (en) * | 2011-05-27 | 2013-12-01 | Leader Machine Co Ltd | A drug delivery device with built - in quantitative pusher |
WO2012177595A1 (en) | 2011-06-21 | 2012-12-27 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
AR088218A1 (en) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | USEFUL HETEROCICLICAL COMPOUNDS AS PI3K INHIBITORS |
AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CA2842524C (en) | 2011-07-22 | 2020-07-14 | Massachusetts Institute Of Technology | Activators of class i histone deacetylases (hdacs) and uses thereof |
US9408972B2 (en) * | 2011-08-02 | 2016-08-09 | Pharmajet, Inc. | Needle-free injection device |
EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013036787A2 (en) | 2011-09-09 | 2013-03-14 | Greenlight Biosciences, Inc. | Cell-free preparation of carbapenems |
CA2848147C (en) | 2011-09-09 | 2021-08-24 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
WO2013039861A2 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
US9750565B2 (en) | 2011-09-30 | 2017-09-05 | Medtronic Advanced Energy Llc | Electrosurgical balloons |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
CN108929375A (en) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | Peptidomimetic macrocyclic compound |
US8870864B2 (en) | 2011-10-28 | 2014-10-28 | Medtronic Advanced Energy Llc | Single instrument electrosurgery apparatus and its method of use |
WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
GB201120000D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
GB201119999D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
IN2014CN03873A (en) | 2011-12-13 | 2015-10-16 | Pharmajet Inc | |
KR20140102759A (en) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | Modified nucleoside, nucleotide, and nucleic acid compositions |
CN113398126A (en) | 2011-12-16 | 2021-09-17 | 佛罗里达大学研究基金会 | Use of 4' -deferthionin analogues |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
US8927500B2 (en) | 2012-02-15 | 2015-01-06 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
US9273084B2 (en) | 2012-04-06 | 2016-03-01 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
WO2013151697A1 (en) | 2012-04-06 | 2013-10-10 | President And Fellows Of Harvard College | Methods and compounds for identifying glycosyltransferase inhibitors |
WO2013152279A1 (en) | 2012-04-06 | 2013-10-10 | President And Fellows Of Harvard College | Chemoenzymatic methods for synthesizing moenomycin analogs |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
MX2014013678A (en) | 2012-05-10 | 2015-02-04 | Massachusetts Inst Technology | Agents for influenza neutralization. |
CA2875683A1 (en) | 2012-06-05 | 2013-12-12 | The Australian National University | Vaccination with interleukin-4 antagonists |
US9226792B2 (en) | 2012-06-12 | 2016-01-05 | Medtronic Advanced Energy Llc | Debridement device and method |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
JP2015525794A (en) | 2012-08-06 | 2015-09-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Method for eliciting an immune response against RSV and Bordetella pertussis in infants |
AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
AU2013306098A1 (en) | 2012-08-18 | 2015-02-12 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
HUE054444T2 (en) | 2012-09-26 | 2021-09-28 | Harvard College | Proline-locked stapled peptides and uses thereof |
US20150225471A1 (en) | 2012-10-01 | 2015-08-13 | President And Fellows Of Harvard College | Stabilized polypeptide insulin receptor modulators |
US11234760B2 (en) | 2012-10-05 | 2022-02-01 | Medtronic Advanced Energy Llc | Electrosurgical device for cutting and removing tissue |
JP6321662B2 (en) | 2012-10-12 | 2018-05-09 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | GSK3 inhibitor and method of use thereof |
US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
US9657076B2 (en) | 2012-10-23 | 2017-05-23 | Emory University | GM-CSF and IL-4 conjugates, compositions, and methods related thereto |
US9982034B2 (en) | 2012-10-24 | 2018-05-29 | Platelet Targeted Therapeutics, Llc | Platelet targeted treatment |
JP6526563B2 (en) | 2012-11-01 | 2019-06-05 | エイルロン セラピューティクス,インコーポレイテッド | Disubstituted amino acids and methods for their preparation and use |
PT2914296T (en) | 2012-11-01 | 2018-10-30 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
US9567301B2 (en) | 2012-11-02 | 2017-02-14 | Dana-Farber Cancer Institute, Inc. | Pyrrol-1-yl benzoic acid derivatives useful as myc inhibitors |
CA2869676C (en) | 2012-11-21 | 2015-06-23 | Topokine Therapeutics, Inc. | Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat |
JP6408478B2 (en) | 2012-11-26 | 2018-10-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Trioxacalcin, trioxacalcin-antibody complex and use thereof |
JP6144355B2 (en) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Chemically modified mRNA |
JP6678455B2 (en) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | PRMT5 inhibitors and uses thereof |
US8940726B2 (en) | 2012-12-21 | 2015-01-27 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
US8906900B2 (en) | 2012-12-21 | 2014-12-09 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2897941A1 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
WO2014124228A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
JP6518597B2 (en) | 2013-02-07 | 2019-05-22 | マサチューセッツ インスティテュート オブ テクノロジー | Human adaptation of H5 influenza |
KR20150131244A (en) | 2013-03-13 | 2015-11-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Stapled and stitched polypeptides and uses thereof |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
NZ629037A (en) | 2013-03-15 | 2017-04-28 | Infinity Pharmaceuticals Inc | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US10492990B2 (en) | 2013-03-15 | 2019-12-03 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
AU2014248090B2 (en) | 2013-04-03 | 2018-08-02 | N-Fold Llc | Novel nanoparticle compositions |
CN111825733A (en) | 2013-04-04 | 2020-10-27 | 哈佛大学的校长及成员们 | Macrolides and methods of making and using the same |
ES2774330T3 (en) | 2013-04-09 | 2020-07-20 | Massachusetts Inst Technology | Drug supply polymer and uses thereof |
WO2014179464A1 (en) | 2013-04-30 | 2014-11-06 | Massachusetts Institute Of Technology | Human adaptation of h3 influenza |
US9315472B2 (en) | 2013-05-01 | 2016-04-19 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
NO2753788T3 (en) | 2013-05-10 | 2018-06-16 | ||
DK3003309T3 (en) | 2013-05-30 | 2020-12-14 | Infinity Pharmaceuticals Inc | Treatment of cancer with PI3 kinase isoform modulators |
WO2014197723A2 (en) | 2013-06-05 | 2014-12-11 | Massachusetts Institute Of Technology | Human adaptation of h7 ha |
EP3030239A4 (en) | 2013-06-11 | 2017-03-08 | Kala Pharmaceuticals, Inc. | Urea derivatives and uses thereof |
CN105492460A (en) | 2013-06-14 | 2016-04-13 | 哈佛大学的校长及成员们 | Stabilized polypeptide insulin receptor modulators |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
EP3013347B1 (en) | 2013-06-27 | 2019-12-11 | Academia Sinica | Glycan conjugates and use thereof |
BR112016001457A2 (en) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES |
BR112016002494A2 (en) | 2013-08-05 | 2017-09-05 | Greenlight Biosciences Inc | PROTEINS CONSTRUCTED WITH A PROTEASE CLEAVAGE SITE, NUCLEIC ACID, VECTOR, CELL AND PROCESS ENGINEERING A RECOMBINANT PROTEIN AND A LARGE NUMBER OF NUCLEIC ACID VARIANTS THAT ENCODE RECOMBINANT PROTEINS |
CA2919773A1 (en) | 2013-08-05 | 2015-02-12 | Glaxosmithkline Biologicals S.A. | Combination immunogenic compositions |
TWI532511B (en) * | 2013-08-16 | 2016-05-11 | 京華堂實業股份有限公司 | A needleless drug-injecting system and a drug-injecting method thereof |
CN105682666B (en) | 2013-09-06 | 2021-06-01 | 中央研究院 | Activation of human iNKT cells using glycolipids |
PE20160685A1 (en) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | HETEROCYCLIC COMPOUNDS AND USES OF THEM |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9982009B2 (en) | 2013-10-15 | 2018-05-29 | Massachusetts Institute Of Technology | Methods for treating polycystic kidney disease and polycystic liver disease |
WO2015057958A2 (en) | 2013-10-16 | 2015-04-23 | Massachusetts Institute Of Technology | Enterobactin conjugates and uses thereof |
JP6491202B2 (en) | 2013-10-18 | 2019-03-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Polycyclic inhibitors of cyclin dependent kinase 7 (CDK 7) |
ES2676734T3 (en) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Heteroatomic compounds useful for the treatment of proliferative diseases |
US20160244452A1 (en) | 2013-10-21 | 2016-08-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6426194B2 (en) | 2013-11-01 | 2018-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | Crystalline forms of therapeutic compounds and uses thereof |
JP6306700B2 (en) | 2013-11-01 | 2018-04-04 | ユニバーシティ オブ オスロUniversity of Oslo | Modified albumin and use thereof |
US9993541B2 (en) | 2013-11-13 | 2018-06-12 | University Of Oslo | Outer membrane vesicles and uses thereof |
EP3069138B1 (en) | 2013-11-15 | 2019-01-09 | Oslo Universitetssykehus HF | Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof |
US10314647B2 (en) | 2013-12-23 | 2019-06-11 | Medtronic Advanced Energy Llc | Electrosurgical cutting instrument |
EA201891279A1 (en) | 2013-12-24 | 2019-01-31 | Президент Энд Феллоус Оф Гарвард Колледж | ANALOGUES OF CORTISTATIN, THEIR SYNTHESIS AND APPLICATIONS |
US9982041B2 (en) | 2014-01-16 | 2018-05-29 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
JP2017504651A (en) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Use of diazepan derivatives |
US10813686B2 (en) | 2014-02-26 | 2020-10-27 | Medtronic Advanced Energy Llc | Electrosurgical cutting instrument |
JP6625071B2 (en) | 2014-03-07 | 2019-12-25 | ザ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Non-drug CRMP2 peptides targeting sodium channels for chronic pain |
SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
TWI687428B (en) | 2014-03-27 | 2020-03-11 | 中央研究院 | Reactive labelling compounds and uses thereof |
ES2868305T3 (en) | 2014-03-28 | 2021-10-21 | Univ Washington Through Its Center For Commercialization | Vaccines against breast and ovarian cancer |
US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015168079A1 (en) | 2014-04-29 | 2015-11-05 | Infinity Pharmaceuticals, Inc. | Pyrimidine or pyridine derivatives useful as pi3k inhibitors |
WO2015168380A1 (en) | 2014-04-30 | 2015-11-05 | Massachusetts Institute Of Technology | Siderophore-based immunization against gram-negative bacteria |
CN106573032B (en) | 2014-05-21 | 2022-03-18 | 哈佛大学的校长及成员们 | RAS inhibitory peptides and uses thereof |
AU2015267045B2 (en) | 2014-05-27 | 2021-02-25 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
CN106573971A (en) | 2014-05-27 | 2017-04-19 | 中央研究院 | Anti-CD20 glycoantibodies and uses thereof |
EP3149161B1 (en) | 2014-05-27 | 2021-07-28 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
TWI732738B (en) | 2014-05-28 | 2021-07-11 | 中央研究院 | Anti-tnf-alpha glycoantibodies and uses thereof |
EP3154576A1 (en) | 2014-06-13 | 2017-04-19 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
SI3157916T1 (en) | 2014-06-19 | 2019-05-31 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
US10188661B2 (en) | 2014-06-27 | 2019-01-29 | Topokine Therapeutics, Inc. | Topical dosage regimen |
WO2016004202A1 (en) | 2014-07-02 | 2016-01-07 | Massachusetts Institute Of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
EP3169699A4 (en) | 2014-07-18 | 2018-06-20 | The University of Washington | Cancer vaccine compositions and methods of use thereof |
US10736966B2 (en) | 2014-08-12 | 2020-08-11 | Massachusetts Institute Of Technology | Brush-poly (glycoamidoamine)-lipids and uses thereof |
US9974599B2 (en) | 2014-08-15 | 2018-05-22 | Medtronic Ps Medical, Inc. | Multipurpose electrosurgical device |
WO2016040369A2 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
US10905739B2 (en) | 2014-09-24 | 2021-02-02 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
EP3204039B1 (en) | 2014-10-10 | 2022-06-08 | The Regents Of The University Of Michigan | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease |
TN2017000157A1 (en) | 2014-10-21 | 2018-10-19 | Ariad Pharma Inc | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine |
US20180015101A1 (en) | 2014-10-28 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for antigen-specific tolerance |
AR102547A1 (en) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | VACCINES AGAINST DISEASE OF HANDS, FEET AND MOUTH AND MANUFACTURING METHODS AND THEIR USE |
AR102548A1 (en) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | VACCINES AGAINST HAND, FEET AND MOUTH DISEASE AND MANUFACTURING AND USE METHODS |
EP3461904A1 (en) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
US10253045B2 (en) | 2014-11-26 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of a therapeutic compound and uses thereof |
EP3230272B1 (en) | 2014-12-10 | 2020-08-19 | Kala Pharmaceuticals, Inc. | 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof |
AU2015369707B2 (en) | 2014-12-23 | 2020-07-23 | Sloan-Kettering Institute For Cancer Research | Polymorph of granaticin B |
WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
EP3248005B1 (en) | 2015-01-24 | 2020-12-09 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
US10188456B2 (en) | 2015-02-18 | 2019-01-29 | Medtronic Xomed, Inc. | Electrode assembly for RF energy enabled tissue debridement device |
US10376302B2 (en) | 2015-02-18 | 2019-08-13 | Medtronic Xomed, Inc. | Rotating electrical connector for RF energy enabled tissue debridement device |
WO2016134156A1 (en) | 2015-02-18 | 2016-08-25 | Medtronic Xomed, Inc. | Rf energy enabled tissue debridement device |
EP4226937A3 (en) | 2015-03-05 | 2023-09-27 | Northwestern University | Non-neuroinvasive viruses and uses thereof |
MX2017011834A (en) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof. |
WO2016154010A1 (en) | 2015-03-20 | 2016-09-29 | Makidon Paul | Immunogenic compositions for use in vaccination against bordetella |
CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
MX2017012665A (en) | 2015-03-30 | 2018-04-24 | Greenlight Biosciences Inc | Cell-free production of ribonucleic acid. |
US10570104B2 (en) | 2015-04-27 | 2020-02-25 | University Of Florida Research Foundation, Incorporated | Metabolically programmed metal chelators and uses thereof |
WO2016178591A2 (en) | 2015-05-05 | 2016-11-10 | Gene Predit, Sa | Genetic markers and treatment of male obesity |
EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
US10201618B2 (en) | 2015-06-19 | 2019-02-12 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof |
WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US11389227B2 (en) | 2015-08-20 | 2022-07-19 | Medtronic Advanced Energy Llc | Electrosurgical device with multivariate control |
US11051875B2 (en) | 2015-08-24 | 2021-07-06 | Medtronic Advanced Energy Llc | Multipurpose electrosurgical device |
EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
EP3347372A4 (en) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of mcl-1 |
KR20180051576A (en) | 2015-09-11 | 2018-05-16 | 다나-파버 캔서 인스티튜트 인크. | Acetamide thienotriazolol diazepines and their uses |
RU2750164C2 (en) | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Cyanothienotriazolodiazepines and methods for their use |
US20180256750A1 (en) | 2015-09-17 | 2018-09-13 | Moderna Therapeutics, Inc. | Polynucleotides containing a stabilizing tail region |
AU2016324310B2 (en) | 2015-09-17 | 2021-04-08 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2017059389A1 (en) | 2015-10-01 | 2017-04-06 | Kythera Biopharmaceuticals, Inc. | Compositions comprising a statin for use in methods of adipolysis |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
WO2017091673A2 (en) | 2015-11-25 | 2017-06-01 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibtors and uses thereof |
US10596248B2 (en) | 2015-12-09 | 2020-03-24 | Jingang Medicine (Australia) Pty Ltd | Immunomodulating composition for treatment |
US10716612B2 (en) | 2015-12-18 | 2020-07-21 | Medtronic Advanced Energy Llc | Electrosurgical device with multiple monopolar electrode assembly |
PL3394030T3 (en) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
TW201808978A (en) | 2016-03-08 | 2018-03-16 | 中央研究院 | Methods for modular synthesis of N-glycans and arrays thereof |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
EP4293104A3 (en) | 2016-04-06 | 2024-04-24 | Greenlight Biosciences, Inc. | Cell-free production of ribonucleic acid |
US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
SG10201913650WA (en) | 2016-06-03 | 2020-03-30 | Sanofi Pasteur Inc | Modification of engineered influenza hemagglutinin polypeptides |
US10105449B2 (en) | 2016-06-07 | 2018-10-23 | Massachusetts Institute Of Technology | Drug delivery polymers and uses thereof |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
AU2017286606A1 (en) | 2016-06-14 | 2018-12-13 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
CN109862908B (en) | 2016-08-05 | 2023-05-02 | 圣诺菲·帕斯图尔公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
MX2019001341A (en) | 2016-08-05 | 2019-07-04 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
JP7213549B2 (en) | 2016-08-22 | 2023-01-27 | シーエイチオー ファーマ インコーポレイテッド | Antibodies, Binding Fragments, and Methods of Use |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018096396A1 (en) | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
HUE060693T2 (en) | 2017-03-15 | 2023-04-28 | Modernatx Inc | Compound and compositions for intracellular delivery of therapeutic agents |
US11555031B2 (en) | 2017-03-20 | 2023-01-17 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
JP7157075B2 (en) | 2017-04-05 | 2022-10-19 | ザ ブロード インスティテュート,インコーポレーテッド | Tricyclic compounds and their use as glycogen synthase kinase 3 (GSK3) inhibitors |
US20210198200A1 (en) | 2017-06-14 | 2021-07-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
US11612647B2 (en) | 2017-06-23 | 2023-03-28 | University Of Maryland, Baltimore | Immunogenic compositions |
WO2019013789A1 (en) | 2017-07-12 | 2019-01-17 | Curza Global, Llc | Antimicrobial compounds |
WO2019013790A1 (en) | 2017-07-12 | 2019-01-17 | Curza Global, Llc | Antimicrobial compounds and uses thereof |
JP7275111B2 (en) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | Method for producing lipid nanoparticles |
US20220118076A1 (en) | 2017-09-07 | 2022-04-21 | University Of Oslo | Vaccine molecules |
EP3678699A1 (en) | 2017-09-07 | 2020-07-15 | University Of Oslo | Vaccine molecules |
AU2018347405B2 (en) | 2017-10-11 | 2022-02-03 | Greenlight Biosciences, Inc. | Methods and compositions for nucleoside triphosphate and ribonucleic acid production |
US11730802B2 (en) | 2017-11-03 | 2023-08-22 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
US11786477B2 (en) | 2017-12-01 | 2023-10-17 | North Carolina State University | Fibrin particles and methods of making the same |
GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
CA3113436A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
CN113924292A (en) | 2019-01-16 | 2022-01-11 | 库扎环球有限责任公司 | Antimicrobial compounds and methods |
CN113825748A (en) | 2019-01-16 | 2021-12-21 | 库扎环球有限责任公司 | Antimicrobial compounds and methods |
CA3128215A1 (en) | 2019-01-31 | 2020-08-06 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
WO2020168466A1 (en) | 2019-02-19 | 2020-08-27 | Stemirna Therapeutics Co., Ltd. | Modified nucleoside and synthetic methods thereof |
WO2021021729A1 (en) | 2019-07-31 | 2021-02-04 | Sanofi Pasteur Inc. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
EP4003296A1 (en) | 2019-07-31 | 2022-06-01 | ModernaTX, Inc. | Compositions and methods for delivery of rna interference agents to immune cells |
AU2020384885A1 (en) | 2019-11-13 | 2022-06-09 | Curza Global, Llc | Antimicrobial compounds and methods |
EP4077994A4 (en) | 2019-12-19 | 2024-01-03 | Saint Gobain Performance Plastics Corp | Poppet, assembly, and methods of assembling and using the same |
CA3169669A1 (en) | 2020-01-31 | 2021-08-05 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
WO2021173965A1 (en) | 2020-02-28 | 2021-09-02 | Massachusetts Institute Of Technology | Identification of variable influenza residues and uses thereof |
WO2021195089A1 (en) | 2020-03-23 | 2021-09-30 | Sorrento Therapeutics, Inc. | Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof |
WO2021231729A1 (en) | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
WO2022092294A1 (en) | 2020-10-30 | 2022-05-05 | 学校法人慶應義塾 | Novel treatment and prevention of sarcopenia-related diseases |
JPWO2022092295A1 (en) | 2020-10-30 | 2022-05-05 | ||
AR124267A1 (en) | 2020-12-09 | 2023-03-01 | Genentech Inc | HIGH THROUGH METHODS FOR PREPARING LIPID NANOPARTICLES AND THEIR USES |
EP4305088A1 (en) | 2021-03-09 | 2024-01-17 | Massachusetts Institute of Technology | Branched poly(-amino esters) for the delivery of nucleic acids |
TW202313065A (en) | 2021-05-28 | 2023-04-01 | 美商季卡尼醫療公司 | Compounds for treating genetic diseases |
WO2023018817A1 (en) | 2021-08-11 | 2023-02-16 | Sanofi Pasteur Inc. | Truncated influenza neuraminidase and methods of using the same |
WO2023039108A1 (en) | 2021-09-08 | 2023-03-16 | Affinivax, Inc. | Coronavirus vaccine |
CA3233926A1 (en) | 2021-10-08 | 2023-04-13 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
WO2023081798A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
WO2023079113A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
WO2023114889A1 (en) | 2021-12-16 | 2023-06-22 | Modernatx, Inc. | Processes for preparing lipid nanoparticles |
WO2023129963A1 (en) | 2021-12-30 | 2023-07-06 | Curza Global, Llc | Antimicrobial compounds and methods |
WO2023144206A1 (en) | 2022-01-27 | 2023-08-03 | Sanofi Pasteur | Modified vero cells and methods of using the same for virus production |
WO2023177579A1 (en) | 2022-03-14 | 2023-09-21 | Sanofi Pasteur Inc. | Machine-learning techniques in protein design for vaccine generation |
WO2023193002A1 (en) | 2022-04-01 | 2023-10-05 | Modernatx, Inc. | Cross mixers for lipid nanoparticle production, and methods of operating the same |
WO2023235380A1 (en) | 2022-06-01 | 2023-12-07 | Zikani Therapeutics, Inc. | Macrolides for treating genetic diseases |
WO2023250513A1 (en) | 2022-06-24 | 2023-12-28 | Zikani Therapeutics, Inc. | 13-membered macrolide compounds for treating diseases mediated by abnormal protein translation |
WO2024026487A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
WO2024026482A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses |
WO2024049994A1 (en) | 2022-09-01 | 2024-03-07 | Zikani Therapeutics, Inc. | Treatment of familial adenomatous polyopsis using a 13-membered macrolide |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2821981A (en) * | 1954-07-21 | 1958-02-04 | Geoffrey W Walker | Multi-shot inoculant injector instrument with adjustable ejection pressure control |
US4475905A (en) * | 1982-09-30 | 1984-10-09 | Himmelstrup Anders B | Injection device |
US4944726A (en) * | 1988-11-03 | 1990-07-31 | Applied Vascular Devices | Device for power injection of fluids |
US5399163A (en) * | 1992-07-24 | 1995-03-21 | Bioject Inc. | Needleless hypodermic injection methods and device |
US5505697A (en) * | 1994-01-14 | 1996-04-09 | Mckinnon, Jr.; Charles N. | Electrically powered jet injector |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2704543A (en) * | 1955-03-22 | Hypo jet injector | ||
US1742497A (en) * | 1925-01-15 | 1930-01-07 | Fairleigh S Dickinson | Hypodermic syringe |
US2025219A (en) * | 1927-03-25 | 1935-12-24 | Arthur E Smith | Hypodermic syringe |
US2101140A (en) * | 1935-03-23 | 1937-12-07 | Raymond W Hege | Automatic injecting syringe device |
US2380534A (en) * | 1941-04-26 | 1945-07-31 | Marshall L Lockhart | Hypodermic injector |
US2322245A (en) * | 1943-05-20 | 1943-06-22 | Marshall L Lockhart | Ypodermic injector and method of use thereof |
US2547009A (en) * | 1944-10-17 | 1951-04-03 | William D Huston | Telemetering system |
US2605763A (en) * | 1948-01-31 | 1952-08-05 | Becton Dickinson Co | Injection device |
US2680439A (en) * | 1948-09-08 | 1954-06-08 | Arnold K Sutermeister | High-pressure injection device |
US2688968A (en) * | 1949-05-14 | 1954-09-14 | Scherer Corp R P | Hypo jet ampoule |
US2737946A (en) * | 1949-09-01 | 1956-03-13 | Jr George N Hein | Hypodermic injection apparatus |
US2653602A (en) * | 1950-06-17 | 1953-09-29 | Becton Dickinson Co | Injection device |
US2754818A (en) * | 1950-06-24 | 1956-07-17 | Scherer Corp R P | Hypo jet injector |
US2764977A (en) * | 1951-05-24 | 1956-10-02 | Becton Dickinson Co | Hypodermic injection mechanism |
US2821193A (en) * | 1952-07-22 | 1958-01-28 | Geoffrey W Walker | Multiple injection inoculator instrument |
US2714887A (en) * | 1954-04-26 | 1955-08-09 | Scherer Corp R P | Intradermal injector |
US2816543A (en) * | 1954-07-12 | 1957-12-17 | Scherer Corp R P | Hypodermic injector |
US2902995A (en) * | 1954-10-11 | 1959-09-08 | Abbott Lab | Hypodermic syringe and needle hub structure |
US3110309A (en) * | 1960-08-15 | 1963-11-12 | Brunswick Corp | Plastic cartridge needle assembly |
NL268186A (en) * | 1960-08-15 | |||
US3167071A (en) * | 1961-07-17 | 1965-01-26 | Scherer Corp R P | Apparatus for administering intradermal injections |
US3179107A (en) * | 1962-11-21 | 1965-04-20 | Becton Dickinson Co | Hypodermic unit with an improved mounting for a replaceable needle assembly |
BE643768A (en) * | 1963-02-18 | |||
US3292621A (en) * | 1963-07-19 | 1966-12-20 | Oscar H Banker | Jet type protable inoculator |
US3292622A (en) * | 1964-09-21 | 1966-12-20 | Oscar H Banker | Power operated inoculator |
US3424154A (en) * | 1965-11-08 | 1969-01-28 | Charles W Kinsley | Injection system |
US3515130A (en) * | 1966-09-21 | 1970-06-02 | Yuryo Kikakuhin Kenkyusho Kk | Jet-injection hypodermic device |
US3490451A (en) * | 1967-11-13 | 1970-01-20 | Scherer Corp R P | Hypodermic jet injector nozzle |
US3561443A (en) * | 1968-09-06 | 1971-02-09 | Oscar H Banker | Inoculator gun with delayed action |
US3557784A (en) * | 1968-12-24 | 1971-01-26 | Walter A Shields | Syringe |
US3688765A (en) * | 1969-10-03 | 1972-09-05 | Jack S Gasaway | Hypodermic injection device |
US3695266A (en) * | 1970-06-18 | 1972-10-03 | Maurice G Lussier | Needleless sequential dosing syringe |
US3714943A (en) * | 1970-12-01 | 1973-02-06 | H Yanof | Medicament injectors |
US3855380A (en) * | 1971-06-09 | 1974-12-17 | Wheeling Stamping Co | Method for manufacturing unitary, seamless, collapsible thermoplastic tubes |
US3853125A (en) * | 1971-10-05 | 1974-12-10 | W Clark | Disposable needleless injector |
US3802430A (en) * | 1972-06-30 | 1974-04-09 | L Arnold | Disposable pyrotechnically powered injector |
US3945383A (en) * | 1974-08-08 | 1976-03-23 | Smithkline Corporation | Unit dose ampul for jet injector |
US3945379A (en) * | 1974-08-08 | 1976-03-23 | Smithkline Corporation | Injection device |
JPS51130094A (en) * | 1975-05-08 | 1976-11-12 | Asahi Chemical Ind | Twoostage pressure injector |
US4124024A (en) * | 1977-03-03 | 1978-11-07 | Schwebel Paul R | Disposable hypodermic injection ampule |
US4284459A (en) * | 1978-07-03 | 1981-08-18 | The Kendall Company | Method for making a molded catheter |
BR7806153A (en) * | 1978-09-19 | 1980-04-01 | Halen Elliot Brasil Ind Com Eq | HYPODERMIC PRESSURE INJECTOR FOR INTERMITTENT VACCINATION |
US4252159A (en) * | 1979-04-02 | 1981-02-24 | Maki Eugene B | Dosage device |
US4329988A (en) * | 1980-12-23 | 1982-05-18 | Survival Technology, Inc. | Plural injection assembly |
US4421508A (en) * | 1981-02-24 | 1983-12-20 | Cohen Edgar C | Vacuum-compression injector |
US4403989A (en) * | 1981-09-14 | 1983-09-13 | Syntex (U.S.A.) Inc. | Injection device |
US4516967A (en) * | 1981-12-21 | 1985-05-14 | Kopfer Rudolph J | Wet-dry compartmental syringe |
CA1178503A (en) * | 1982-05-27 | 1984-11-27 | Health-Mor Personal Care Corporation | Needleless hypodermic injector |
DE3372172D1 (en) * | 1982-10-27 | 1987-07-30 | Duphar Int Res | Hypodermic syringe having a telescopic assembly between cartridge and medicament holder |
US4507113A (en) * | 1982-11-22 | 1985-03-26 | Derata Corporation | Hypodermic jet injector |
HU186718B (en) * | 1983-06-29 | 1985-09-30 | Radelkis Electrokemiai | Automatic needleless syringe operable by cardox cylinder suitable for personal giving injection e.g. insulin |
US4581014A (en) * | 1984-04-03 | 1986-04-08 | Ivac Corporation | Fluid infusion system |
BR8404286A (en) * | 1984-08-28 | 1986-04-08 | Sergio Landau | PRESSURE HYPODERMIC SYRINGE |
US4759756A (en) * | 1984-09-14 | 1988-07-26 | Baxter Travenol Laboratories, Inc. | Reconstitution device |
US4596556A (en) * | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4680027A (en) * | 1985-12-12 | 1987-07-14 | Injet Medical Products, Inc. | Needleless hypodermic injection device |
EP0250022A3 (en) * | 1986-06-17 | 1988-06-22 | SICIM SpA | Portable endermic injector |
US4717384A (en) * | 1987-01-15 | 1988-01-05 | Pneu Dart Inc. | Pneumatic hypodermic syringe pole |
US4722728A (en) * | 1987-01-23 | 1988-02-02 | Patents Unlimited, Ltd. | Needleless hypodermic injector |
US4886495A (en) * | 1987-07-08 | 1989-12-12 | Duoject Medical Systems Inc. | Vial-based prefilled syringe system for one or two component medicaments |
EP0294272B1 (en) * | 1987-05-26 | 1992-03-18 | Claude Accaries | Needleless injector, especially for dental use |
US5080648A (en) * | 1987-06-08 | 1992-01-14 | Antonio Nicholas F D | Hypodermic fluid dispenser |
US5569190A (en) * | 1987-06-08 | 1996-10-29 | D'antonio; Nicholas F. | Hypodermic fluid dispenser |
US4790824A (en) * | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) * | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) * | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
AU628029B2 (en) * | 1987-11-16 | 1992-09-10 | Sy-Quest International Limited | Improved apparatus for hypodermic injection of liquids |
US5073165A (en) * | 1988-02-05 | 1991-12-17 | Marpam International, Inc. | Hypodermic jet injector and cartridge therefor |
US4874367A (en) * | 1988-02-05 | 1989-10-17 | Marpam International, Inc. | Hypodermic jet injector and cartridge therefor |
FR2627698A1 (en) * | 1988-02-26 | 1989-09-01 | Vci Corp | Medicament cartridge for vacuum compression injector |
US4913699A (en) * | 1988-03-14 | 1990-04-03 | Parsons James S | Disposable needleless injection system |
BR8801952A (en) * | 1988-04-22 | 1989-11-14 | Sergio Landau | DISPOSABLE CAPSULE, NOT RE-USABLE, CONTAINING INDIVIDUAL DOSE OF VACCINE TO BE HYPODERMICALLY INJECTED, WITHOUT NEEDLE, WITH PRESSURE INJECTOR |
US5024656A (en) * | 1988-08-30 | 1991-06-18 | Injet Medical Products, Inc. | Gas-pressure-regulated needleless injection system |
FR2648352A1 (en) * | 1989-06-16 | 1990-12-21 | Merieux Inst | IMPROVEMENT IN DOSAGE-FREE NEEDLE INJECTION DEVICES CONTAINED IN CARTRIDGES AND CARTRIDGES FOR USE IN SUCH AN APPARATUS |
US4944736A (en) * | 1989-07-05 | 1990-07-31 | Holtz Leonard J | Adaptor cap for centering, sealing, and holding a syringe to a bottle |
CA1325149C (en) * | 1989-08-31 | 1993-12-14 | Gavin Mcgregor | Variable intensity remote controlled needleless injector |
US4997430A (en) * | 1989-09-06 | 1991-03-05 | Npbi Nederlands Produktielaboratorium Voor Bloedtransfusieapparatuur En Infusievloeistoffen B.V. | Method of and apparatus for administering medicament to a patient |
US5312335A (en) * | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) * | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5078690A (en) * | 1990-01-11 | 1992-01-07 | Accumed Systems, Incorporated | High pressure syringe |
US5062830A (en) * | 1990-04-04 | 1991-11-05 | Derata Corporation | Dry disposable nozzle assembly for medical jet injector |
GB9118204D0 (en) * | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
US5312577A (en) * | 1992-05-08 | 1994-05-17 | Bioject Inc. | Method for manufacturing an ampule |
US5472022A (en) * | 1993-11-02 | 1995-12-05 | Genentech, Inc. | Injection pen solution transfer apparatus and method |
US5466220A (en) * | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
-
1997
- 1997-05-19 US US08/858,249 patent/US5993412A/en not_active Expired - Fee Related
-
1998
- 1998-04-22 DE DE69820460T patent/DE69820460T2/en not_active Expired - Lifetime
- 1998-04-22 CA CA002290777A patent/CA2290777C/en not_active Expired - Fee Related
- 1998-04-22 AU AU72549/98A patent/AU7254998A/en not_active Abandoned
- 1998-04-22 WO PCT/US1998/008161 patent/WO1998052632A1/en active IP Right Grant
- 1998-04-22 EP EP98919849A patent/EP1011763B1/en not_active Expired - Lifetime
-
1999
- 1999-11-18 GB GBGB9927246.0A patent/GB9927246D0/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2821981A (en) * | 1954-07-21 | 1958-02-04 | Geoffrey W Walker | Multi-shot inoculant injector instrument with adjustable ejection pressure control |
US4475905A (en) * | 1982-09-30 | 1984-10-09 | Himmelstrup Anders B | Injection device |
US4944726A (en) * | 1988-11-03 | 1990-07-31 | Applied Vascular Devices | Device for power injection of fluids |
US5399163A (en) * | 1992-07-24 | 1995-03-21 | Bioject Inc. | Needleless hypodermic injection methods and device |
US5505697A (en) * | 1994-01-14 | 1996-04-09 | Mckinnon, Jr.; Charles N. | Electrically powered jet injector |
Non-Patent Citations (1)
Title |
---|
See also references of EP1011763A4 * |
Cited By (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43824E1 (en) | 2001-01-11 | 2012-11-20 | Powder Pharmaceuticals Inc. | Needleless syringe |
US6607510B2 (en) | 2001-11-09 | 2003-08-19 | Bioject Medical Technologies Inc. | Disposable needle-free injection apparatus and method |
US6676630B2 (en) | 2002-06-04 | 2004-01-13 | Bioject Medical Technologies, Inc. | Needle-free injection system |
US6883222B2 (en) | 2002-10-16 | 2005-04-26 | Bioject Inc. | Drug cartridge assembly and method of manufacture |
US7615645B2 (en) | 2003-10-21 | 2009-11-10 | Basf Aktiengesellschaft | Method for the continuous production of aldehydes |
US10335549B2 (en) | 2004-11-22 | 2019-07-02 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US10737028B2 (en) | 2004-11-22 | 2020-08-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US10314977B2 (en) | 2004-11-22 | 2019-06-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US10071203B2 (en) | 2004-11-22 | 2018-09-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US11590286B2 (en) | 2004-11-22 | 2023-02-28 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9056170B2 (en) | 2004-11-22 | 2015-06-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9149579B2 (en) | 2004-11-22 | 2015-10-06 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9833573B2 (en) | 2004-11-22 | 2017-12-05 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9737669B2 (en) | 2004-11-22 | 2017-08-22 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9724471B2 (en) | 2005-02-01 | 2017-08-08 | Kaleo, Inc. | Devices, systems, and methods for medicament delivery |
US10076611B2 (en) | 2005-02-01 | 2018-09-18 | Kaleo, Inc. | Medicament delivery device having an electronic circuit system |
US9327077B2 (en) | 2005-02-01 | 2016-05-03 | Kaleo, Inc. | Medical injector with compliance tracking and monitoring |
US10796604B2 (en) | 2005-02-01 | 2020-10-06 | Kaleo, Inc. | Medical injector simulation device and containers for storing delivery devices |
US10835673B2 (en) | 2005-02-01 | 2020-11-17 | Kaleo, Inc. | Devices, systems, and methods for medicament delivery |
US10918791B2 (en) | 2005-02-01 | 2021-02-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9022980B2 (en) | 2005-02-01 | 2015-05-05 | Kaleo, Inc. | Medical injector simulation device |
US10960155B2 (en) | 2005-02-01 | 2021-03-30 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US10105489B2 (en) | 2005-02-01 | 2018-10-23 | Kaleo, Inc. | Medical injector with compliance tracking and monitoring |
US9278177B2 (en) | 2005-02-01 | 2016-03-08 | Kaleo, Inc. | Medical injector with compliance tracking and monitoring |
US9259539B2 (en) | 2005-02-01 | 2016-02-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9805620B2 (en) | 2005-02-01 | 2017-10-31 | Kaleo, Inc. | Medical injector simulation device |
US10099023B2 (en) | 2005-02-01 | 2018-10-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9238108B2 (en) | 2005-02-01 | 2016-01-19 | Kaleo, Inc. | Medicament delivery device having an electronic circuit system |
US9278182B2 (en) | 2005-02-01 | 2016-03-08 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9555191B2 (en) | 2007-01-22 | 2017-01-31 | Kaleo, Inc. | Apparatus and methods for self-administration of vaccines and other medicaments |
US10258735B2 (en) | 2007-02-05 | 2019-04-16 | Kaleo, Inc. | Apparatus and methods for self-administration of vaccines and other medicaments |
US9358338B2 (en) | 2007-05-04 | 2016-06-07 | Powder Pharmaceuticals Incorporated | Particle cassettes and processes therefor |
US9044546B2 (en) | 2007-05-04 | 2015-06-02 | Powder Pharmaceuticals Incorporated | Particle cassettes and processes therefor |
USD994111S1 (en) | 2008-05-12 | 2023-08-01 | Kaleo, Inc. | Medicament delivery device cover |
US10192464B2 (en) | 2008-07-28 | 2019-01-29 | Kaleo, Inc. | Medicament delivery device configured to produce wireless and audible outputs |
US11263921B2 (en) | 2008-07-28 | 2022-03-01 | Kaleo, Inc. | Medicament delivery device configured to produce wireless and audible outputs |
USD1011520S1 (en) | 2011-01-26 | 2024-01-16 | Kaleo, Inc. | Medicament delivery device and cover assembly |
US10322239B2 (en) | 2011-01-26 | 2019-06-18 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US10342924B2 (en) | 2011-01-26 | 2019-07-09 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
USD994110S1 (en) | 2011-01-26 | 2023-08-01 | Kaleo, Inc. | Medicament delivery device cover |
US10238806B2 (en) | 2011-01-26 | 2019-03-26 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
US9814838B2 (en) | 2011-01-26 | 2017-11-14 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US11426520B2 (en) | 2011-01-26 | 2022-08-30 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
US10143792B2 (en) | 2011-02-28 | 2018-12-04 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9474869B2 (en) | 2011-02-28 | 2016-10-25 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9022022B2 (en) | 2011-02-28 | 2015-05-05 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
WO2012175503A1 (en) * | 2011-06-21 | 2012-12-27 | Sanofi-Aventis Deutschland Gmbh | Medicament delivery device with dose control mechanism |
EP2537546A1 (en) * | 2011-06-21 | 2012-12-26 | Sanofi-Aventis Deutschland GmbH | Medicament delivery device with dose control mechanism |
US9522235B2 (en) | 2012-05-22 | 2016-12-20 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
US10226583B2 (en) | 2012-05-22 | 2019-03-12 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
US10839669B2 (en) | 2012-12-27 | 2020-11-17 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
US10726701B2 (en) | 2012-12-27 | 2020-07-28 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
US9836948B2 (en) | 2012-12-27 | 2017-12-05 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
US9542826B2 (en) | 2012-12-27 | 2017-01-10 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
US9911308B2 (en) | 2012-12-27 | 2018-03-06 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
US10229578B2 (en) | 2012-12-27 | 2019-03-12 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
US10220158B2 (en) | 2014-07-18 | 2019-03-05 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
US10695495B2 (en) | 2015-03-24 | 2020-06-30 | Kaleo, Inc. | Devices and methods for delivering a lyophilized medicament |
US10576206B2 (en) | 2015-06-30 | 2020-03-03 | Kaleo, Inc. | Auto-injectors for administration of a medicament within a prefilled syringe |
US11517674B2 (en) | 2015-06-30 | 2022-12-06 | Kaleo, Inc. | Auto-injectors for administration of a medicament within a prefilled syringe |
US10842938B2 (en) | 2016-12-23 | 2020-11-24 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
US11771830B2 (en) | 2016-12-23 | 2023-10-03 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
US10688244B2 (en) | 2016-12-23 | 2020-06-23 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
US10332623B2 (en) | 2017-01-17 | 2019-06-25 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and event detection |
US11577025B2 (en) | 2017-06-29 | 2023-02-14 | Regeneron Pharmaceuticals, Inc. | Devices and methods for overfilling drug containers |
TWI787906B (en) * | 2017-06-29 | 2022-12-21 | 美商里珍納龍藥品有限公司 | A method of preparing a drug product and a drug product prepared by the method |
WO2019005072A1 (en) * | 2017-06-29 | 2019-01-03 | Regeneron Pharmaceuticals Inc. | Devices and methods for overfilling drug containers |
TWI736704B (en) * | 2017-06-29 | 2021-08-21 | 美商里珍納龍藥品有限公司 | Devices and methods for overfilling drug containers |
US11918785B2 (en) | 2017-06-29 | 2024-03-05 | Regeneron Pharmaceuticals Inc. | Devices and methods for overfilling drug containers |
US11929160B2 (en) | 2018-07-16 | 2024-03-12 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and compliance detection |
US11167087B2 (en) | 2019-08-09 | 2021-11-09 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
Also Published As
Publication number | Publication date |
---|---|
CA2290777C (en) | 2006-07-11 |
CA2290777A1 (en) | 1998-11-26 |
EP1011763B1 (en) | 2003-12-10 |
DE69820460D1 (en) | 2004-01-22 |
EP1011763A1 (en) | 2000-06-28 |
DE69820460T2 (en) | 2004-10-07 |
EP1011763A4 (en) | 2001-03-21 |
US5993412A (en) | 1999-11-30 |
AU7254998A (en) | 1998-12-11 |
GB9927246D0 (en) | 2000-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5993412A (en) | Injection apparatus | |
US20040035491A1 (en) | Method and apparatus for needle-less injection with a degassed fluid | |
US5383851A (en) | Needleless hypodermic injection device | |
CA1157332A (en) | Hydro-pneumatic jet injector | |
JP4771508B2 (en) | Auto-injector powered by pneumatic pressure | |
US6096002A (en) | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method | |
US4717384A (en) | Pneumatic hypodermic syringe pole | |
US6572581B1 (en) | Ergonomic needle-less jet injection apparatus and method | |
US20050192530A1 (en) | Method and apparatus for needle-less injection with a degassed fluid | |
US6428509B1 (en) | Syringe plunger driver system and method | |
US5190523A (en) | Disposable syringe and injector | |
US4596556A (en) | Hypodermic injection apparatus | |
US5891086A (en) | Needle-less injector | |
DK1755709T4 (en) | An injection device | |
CN102802699B (en) | Medicament Delivery Device | |
CN101193672B (en) | Needle-less injector | |
US5788673A (en) | Drug infusion system | |
CA2259560C (en) | Hypodermic jet injector | |
CN104428205A (en) | Venting syringe | |
US10245382B2 (en) | Pneumatic needle-free injection device | |
CN110769873A (en) | Autoinjector with variable plunger force | |
MX2008015462A (en) | Charging mechanism for a needle-free injector. | |
GB2414405A (en) | An injection device having a locking mechanism | |
RU2607955C2 (en) | Needle free injector in the form of rod | |
US20200121848A1 (en) | Injector device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2290777 Country of ref document: CA Ref country code: CA Ref document number: 2290777 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998919849 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998550366 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998919849 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998919849 Country of ref document: EP |